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Chapter 1
Introduction
Molecular imaging can be defined as the visual representation, characterization and
quantification of biological processes at the cellular and subcellular levels within in-
tact living organisms [1]. Generally speaking, molecular imaging involves specialized
instrumentation, used alone or in combination with targeted imaging agents, to vi-
sualize tissue characteristics and/or biochemical markers [2]. The field of molecular
imaging is highly multidisciplinary, drawing from many areas of science, including,
but not limited to, molecular biology, biochemistry, physiology, physics, engineering,
genetics, mathematics, chemistry, pharmacology, immunology, and medicine. Molec-
ular imaging of living subjects can trace its roots back to nuclear medicine, never-
theless many techniques are now possible. In fact, techniques using optical signaling,
as well as signaling using magnetic resonance imaging (MRI), ultrasound (US), Ra-
man, photoacoustics (PA), and computed tomography (CT), have also been steadily
increasing. And although still in its infancy, molecular imaging is showing enormous
promise in the areas of diagnostics, therapy monitoring, drug discovery and devel-
opment, and understanding nanoscale reactions such as protein-protein interactions
and enzymatic conversion.
Biomedical research utilizing small animals such as mice and rats has expanded
dramatically in the past few years as molecular biology and imaging techniques open
new opportunities to investigate models of disease (see chapter 2). The growing
number of mouse and rat experiments, coupled with the increasing number of dedi-
cated small animal imaging systems such as microPET, optical, microCT, microMRI,
2 Chapter 1. Introduction
ultrasound and microSPECT, has led to the development of common technical cen-
ters for imaging small animals. Increasingly sophisticated molecular probes and tool
sets allow researchers to examine multiple processes at once in the same animal by
using different light wavelengths (optical), various molecular imaging probes (PET
and SPECT) and different contrast agents (MRI and CT), as well as to define the
anatomical structures in which these processes take place. This, in turn, has led to a
demand for comprehensive, multimodality imaging facilities that can house animals,
support imaging systems, and provide investigators with the tools, methods, and
other infrastructure necessary for successful imaging experiments [3].
The creation of the Center of Excellence in Preclinical Imaging (CEIP) is part
of this expansions. The CEIP is an Academic/Industry partnership and offers to
universities, research centers and companies know-how and methodologies based on
imaging techniques in order to easy and speed up the process of development of new
diagnostic and therapeutics solutions. In fact, it is equipped with several state of the
art imaging devices: 3 small MRI system, a PET/SPECT and a PET/SPECT/CT
scanners, an Ultra sound and Optical system (see chapter 4).
This thesis deals with the experience in the Center of Excellence in Preclinical
Imaging, CEIP: from the set-up of the PET/SPECT laboratory to the routine ex-
perimental activity.
Chapter 2 presents an overview of the main characteristics of molecular imaging,
explaining why small animal imaging is necessary and describing the features of the
main molecular imaging systems and their applications in the field.
Chapter 3 describes the basic concepts in radioprotection, mainly focusing of the
practical considerations for safe radioisotopes and animal handlings in a PET/SPECT
laboratory.
In chapter 4, after a brief introduction of the Center of Excellence in Preclinical
Imaging (CEIP), the layout of the PET/SPECT laboratory is reported together with
the evaluation of the radiation exposure to both personnel and public, the manage-
ment of the radioactive wastes and residuals and the classification of the areas and
of the workers.
Chapter 5 deeply describes the main hardware and software characteristics of the
3YAP-(S)PET scanner. The YAP-(S)PET User Friendly interface and the reconstruc-
tion algorithms are widely reported.
Finally, chapter 6 describes a few case animal studies performed within the CEIP,
the Center of Excellence in Preclinical Imaging Both longitudinal PET and SPECT
studies are reported, besides a PET/MRI multimodality realized with an hand-made
support that allow to perform the two acquisitions without animal repositioning.
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Chapter 2
The role of preclincal imaging
When Watson and Crick elucidated the double-helical structure of DNA in 1958,
they made the greatest discovery of the XX century in the biological sciences. This
discovery initiated a time in biology in which biological and physical scientists would
strive to unravel the genetic code and its regulated expression, which determines
the genotypic basis for the phenotypes of all the cells within the organism. Today,
intense exploration is taking place in the biological sciences to determine the patterns
of gene expression that encode for normal biological processes, such as replication,
migration, signal transduction of cell communication, and the many other functions
that cells perform. In addition, belief is growing that most diseases result from altered
patterns of gene expression that transition cells to the phenotypes of disease. These
alterations in gene expression can result from interactions with the environment,
hereditary defects, developmental errors, and aging. As a result, biology is coming
together with medicine to design ways to identify these fundamental molecular errors
of disease and develop molecular corrections for them. The general name given to
this emerging field is molecular medicine [4].
As biology and medicine come together, it is important that imaging also merges
with biology to form the technologies referred to as biological or molecular imaging.
Many scientists state that molecular imaging is not a new discipline: nuclear
imaging approaches such as positron emission tomography (PET) and single-photon
emission computed tomography (SPECT) have been using molecular imaging con-
cepts for more than a decade to visualize the biodistribution of labeled compounds
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including analyses of receptor occupancy. In these studies image contrast is not gov-
erned by the anatomical features of the sample but rather by the local concentration
of the radio-labeled reporter compound, i.e., by a molecular property.
Other scientists claim that molecular imaging is a new scientific area merging
concepts of molecular biology with noninvasive imaging technologies. This allows the
study of biological processes in a noninvasive manner. These concepts go beyond
labeling of reporter ligands. They involve the development of a great number of
reporter assays that are used to probe specific biological questions. Is the expression
of a receptor modified under specific pathological conditions? Does the receptor exert
its biological activity? Does it activate its associated signaling cascade? Can these
molecular markers be used as early indicators of a pathological transformation? [5]
A precise definition of molecular imaging is an elusive and perhaps not particularly
important goal [6]. Rather the term reflects a shift in emphasis and a shift in atti-
tude, moving from the undeniably useful, but largely non-specific, diagnostic imaging
approaches that are currently employed in the clinic, to targeting specific genes and
proteins that are known to be linked directly or indirectly to human disease.
The emergence of molecular imaging strategies is largely due to recent unprece-
dented advances in molecular and cell biology techniques, the use of transgenic animal
models, availability of newer imaging drugs and probes that are highly specific, and
successful development of small-animal imaging instrumentation [1]. This creates the
possibility of achieving several important goals in biomedical research:
• to develop noninvasive in vivo imaging methods that reflect specific cellular and
molecular processes, for example, gene expression, or more complex molecular
interactions such as protein-protein interactions.
• to monitor multiple molecular events near-simultaneously.
• to follow trafficking and targeting of cells.
• to optimize drug and gene therapy.
• to image drug effects at a molecular and cellular level.
• to assess disease progression at a molecular pathological level.
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• to create the possibility of achieving all of the above goals of imaging in a
rapid, reproducible and quantitative manner, so as to be able to monitor time-
dependent experimental, developmental, environmental, and therapeutic influ-
ences on gene products in the same animal or patient.
2.1 The importance of small animal models in molec-
ular imaging
Molecular imaging in living subjects offers distinct advantages when compared with
conventional in vitro and cell culture research techniques in biology.
In contrast to cell and tissue culture, in vivo animal models allow the assessment
of phenomena such as tolerances, complementation, and redundancy in biological
pathways. Molecular imaging permits both the temporal and the spatial biodistribu-
tion of a molecular probe and related biological processes to be determined in a more
meaningful manner throughout an intact living subject [1].
Imaging technologies are playing a growing role in animal research, enabling large,
expensive laboratory animals to be studied noninvasively and providing the possibil-
ity of reducing the number of small laboratory animals required in typical longitudinal
studies. As each animal serves as its own individual control, the reproducibility of
data from imaging studies may actually be better than that obtained from tradi-
tional invasive techniques, although this improvement has yet to be demonstrated
unequivocally. Finally, imaging provides a bridge from animal research to human
research.
Since the mid 1980s, the effort to understand mammalian biology and the study
of disease models have caused the mouse to become the animal of choice. More than
90% of all mammals used worldwide in research in the year 2000 were mice [7]. The
rapid rate of reproducibility and short life span of mice aid in keeping down the cost
of maintaining colonies and favor them as a molecular biology research vehicle. In
addition, most human genes have a related mouse gene, allowing mice to be used as
a platform for mimicking many human disease [8]. Furthermore, modern molecular
biology contains the technology to “knock-out” or disable genes, and to insert or
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“knock-in” new ones in order to create many types of transgenic mice. The mouse
genome has been the second mammalian genome to be sequenced after the human
genome [9].
Molecular imaging of living mice offers distinct advantages when investigating
phenotypic abnormalities [1]:
• it eliminates the need to kill such mice as part of their phenotype determination.
• by repetitive imaging it is possible to investigate mutants that are otherwise
difficult to interpret with data taken at a single time point.
• it allows concomitant visual and analytical biological phenotyping of animals.
• it allows the researcher to exercise options of multiple imaging strategies (e.g.,
by using different imaging reporter probes or modalities) in cases in which
simple genetic manipulations could result in a very complex phenotype involving
a large number of pathways and organs.
Moreover, in vivo mouse imaging as an alternative to killing many animals for
histological processing at different time points is also convenient in terms of money.
With each transgenic mouse valued in the 200-300 dollars range, the overall costs of
conventional post mortem biological assays on many animals can mount substantially.
The use of fewer animals in biological assays with molecular imaging would also be
more appealing on ethical grounds. In theory, approval for research projects requiring
large numbers or many separate cohorts of experimental animals could be obtained
more easily [1].
Molecular imaging assays in intact living animals could be of further benefit in
resolving biological questions raised by pharmaceutical scientists. Transgenic animals
are useful in guiding early drug discovery validating the target protein, evaluating test
compounds, determining whether the target is involved in any toxicological effects of
test compounds, and testing the efficacy of compounds to ensure that the compounds
will act as expected in man [1].
In some disciplines, particularly in neuroscience, the rat also remains an important
experimental animal, partly due to the ease of surgical manipulation of the rat brain
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versus the mouse brain (2 g as opposed to 0.45 g). In addition, there is a large
historical knowledge base of both the anatomy and the function of the rat brain,
deriving from many decades during which it was the preferred model [10].
2.2 Molecular imaging instrumentation and techniques
Biological discovery has moved at an accelerated pace in recent years, with consider-
able focus on the transition from in vitro to in vivo models. As such, there has been a
greater need to adapt clinical imaging methods for noninvasive assays of biochemical
processes. Considerable efforts have been directed in recent years toward the develop-
ment of noninvasive, high-resolution, small animal in vivo imaging technologies (see
figure 2.1). The widespread availability and use of miniaturized imaging systems for
rodents are invaluable resources for basic science laboratories. Nonetheless, signifi-
cant challenges remain to be overcome when attempting to image a 30-g mouse as
compared with a 70-kg human, including the size of the subject, the total volume
that must be evaluated, the spatial resolution necessary for obtaining meaningful
anatomical and/or functional data, and the total time spent on acquiring a set of
images [11]. A comparison between human and small animal size can be obtained by
figure 2.2.
In small animal research, the primary goal is to obtain as high a signal as possible
and to localize the signal as accurately as possible with high temporal resolution and
with minimal amount of molecular probe. The ultimate goal is to provide a device
that produces a three-dimensional image of anatomical and biological information
fused together. The various existing imaging technologies differ for the following
main aspects [1]:
• spatial and temporal resolution.
• depth penetration.
• energy used for image generation (ionizing or nonionizing, depending on which
component of the electromagnetic radiation spectrum is exploited for image
generation).
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Figure 2.1: Illustrative examples of the variety of images that can be obtained with different
imaging modalities. (A) microPET whole-body coronal image of a rat injected with 18FDG,
showing uptake of tracer in tissues including muscles, heart, brain, and accumulation in
bladder owing to renal clearance. (B) microCT coronal image of a mouse abdomen after
injection of intravenous iodinated contrast medium. (C) microSPECT coronal image of
a mouse abdomen and pelvis regions after injection of 99mTc methylene diphosphonate,
showing spine, pelvis, tail vertebrae, femurs, and knee joints owing to accumulation of tracer
in bone. (D) Optical reflectance fluorescence image of a mouse showing GFP fluorescence
from the liver, abdomen, spine, and brain. The mouse contains GFP-expressing tumor cells
that have spread to various sites. Images are courtesy of Dr. Hoffman, Anticancer Inc. (E)
microMRI coronal T2-weighted image of a mouse brain. (F) Optical bioluminescence image
of a mouse with a subcutaneous xenograft expressing Renilla luciferase in the left shoulder
region, after tail-vein injection of the substrate coelenterazine. Images were obtained using
a cooled CCD camera. The color image of visible light is superimposed on a photographic
image of the mouse with a scale in photons per second per square centimeter per steradian
(sr) [1].
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Figure 2.2: Relative size of a human, rat and mouse brain [12].
• availability of injectable/biocompatible molecular probes.
• the respective detection threshold of probes for a given technology.
Table 2.1 outlines some of the general characteristics of the imaging modalities
available.
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2.2.1 Radionuclide imaging
The primary advantage of radioactive assays (whether in vivo, ex vivo or in vitro)
is their exquisite sensitivity and the ability, with appropriate care, of radiation de-
tection systems to provide quantitative measurements of radioactivity concentrations
deep inside tissue. Radiolabelled tracers have a long history of being used to elu-
cidate physiology, metabolic pathways and molecular targets [13], and to provide a
high sensitivity tool for molecular imaging studies. A very large number of radio-
labelled tracers have been developed to probe specific biological targets and func-
tions [14], and a growing number are moving into clinical use. An important strength
is the availability of radionuclides of biologically relevant elements, particularly car-
bon, allowing contrast agents to be labelled by direct isotopic substitution. This
allows small biomolecules (many drugs, receptor ligands, etc.) to be labelled without
changing their biochemical properties. Another powerful approach is to create analog
radiotracers, in which deliberate chemical changes are made to a biologically active
molecule to isolate specific pathways or cause specific trapping of a radiotracer in
cells expressing the target of choice. Analog radiotracers are also designed to allow
the use of isotopes of elements that are not found within the molecule of interest, but
that have good imaging properties. Larger biomolecules (peptides, antibodies, RNA,
synthetic macromolecules) are also readily labelled with a wide range of radionuclides
that have excellent properties for imaging. A list of the major radionuclides that are
currently being used for in vivo nuclear imaging is provided in table 2.2. A further
advantage is that nuclear imaging approaches are readily translated to the clinic, as
the majority of the listed radionuclides produce photons with sufficient tissue pen-
etration for studies in man. Disadvantages of nuclear imaging approaches include
obvious factors such as the involvement of ionizing radiation, and more subtle factors
such as the fact that radioactive decay cannot be controlled, hence there is always
non-specific background signal present in an image due to non-specific binding of
radiotracers, residual radiotracer in the circulation and routes of excretion [6].
Nuclear imaging techniques include high resolution (<100 µm) ex vivo autoradio-
graphic techniques using film, phosphor storage plates or real time autoradiographic
systems [15] and in vivo methods using radionuclides that produce appropriate energy
14 Chapter 2. The role of preclincal imaging
photons (gamma-rays, annihilation photons or characteristic x-rays with energies in
the range of 25-511 keV) during decay. The in vivo methods are further broken up
into: single photon imaging that utilize radionuclides with single or multiple uncorre-
lated gamma ray emissions and PET in which radionuclides decay by positron emis-
sion resulting in two simultaneous annihilation photons emitted back-to-back [16].
The development of higher resolution and higher sensitivity animal PET and
SPECT systems is allowing molecular and genomic imaging approaches, tradition-
ally approached by ex vivo autoradiographic methods, to be translated in vivo into
animal models of disease [17,18]. Dramatic improvements in image quality have been
achieved by using novel detector and collimation approaches, and by exploiting the
more favourable environment found in small animal imaging.
One of the advantages of nuclear imaging, say as, compared to optical imaging,
is that the radiation involved is highly penetrating, and so the dependence of the
detected signal on the depth at which it is emitted is fairly small. Even without cor-
rection for scatter and attenuation, nuclear images within small animals can exhibit
fairly high quantitative accuracy in specific circumstances and with the appropriate
calibration object [6].
Radionuclide Half life Energy of principle Imaging modalityphotons (keV)
11C 20.4 mins 511 PET
18F 110 mins 511 PET
64Cu 12.7 h 511 PET
99mTc 6.02 h 140 SPECT
111In 2.83 days 171, 245 SPECT
123I 13.2 h 159 SPECT
124I 4.18 days 511, 603, 723, 1690 PET
125I 60.1 days 27, 31, 35 SPECT
131I 8.04 days 354 SPECT
Table 2.2: Radionuclides commonly used for in vivo nuclear imaging.
2.2.2 Optical imaging
There has been tremendous growth in the use of optical approaches for in vivo imag-
ing of small laboratory animals. This is in part due to the accessibility of optical
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approaches, and also in part because of their extremely high sensitivity. Light is
both scattered and absorbed in tissues, but there is an absorption minimum cor-
responding to wavelengths in the approximate range of 700-950 nm [19]. At these
wavelengths, the light is still readily scattered but the absorption length is on the
order of several centimetres. Thus, light emitted from deep inside a small animal
has a reasonable probability of reaching the surface for external detection. Although
this light has in general scattered many times when it reaches the surface, some posi-
tional information is retained based on the intensity, spatial distribution and spectral
distribution of the emitted light [20]. This region of the electromagnetic spectrum
is known as the “optical window” because of the more favourable characteristics for
imaging through tissue.
At the present time, most studies are based on imaging the intensity of the emitted
light at the surface of the animal with straightforward detector systems that are
amenable for use in biology labs and have the capability of relatively high throughput.
Two distinct contrast mechanisms are being used for molecular and genomic imaging
studies: one involving fluorescence [21], and the other involving bioluminescence [22].
In fluorescence imaging, an external light source, either a laser, or a broadband
source (e.g., a mercury lamp) with an appropriate low-pass filter, is used to excite
fluorescent molecules inside the subject. These fluorescent molecules may be geneti-
cally engineered into a mouse, for example by incorporating the gene for a fluorescent
protein as a reporter gene. Green Fluorescent Protein (GFP) has been widely used
in this manner for cell culture and tissue slice experiments, but is less well suited for
in vivo use because of the relatively short excitation (peak ∼ 470-490 nm) and emis-
sion (peak ∼ 510 nm) wavelengths that place it outside the optical window and in a
part of the spectrum where there is significant autofluorescence of tissue components.
Despite these difficulties, GFP has been used successfully for some in vivo imaging
studies [23]. Subsequently, GFP mutants and other fluorescent proteins have been
discovered that have excitation and emission spectra better suited to in vivo imag-
ing [24–26]. Another approach to introducing fluorescent molecules into an animal is
to use fluorophores (or more recently, fluorescent particles known as quantum dots)
as labels on biologically interesting molecules [27]. This is analogous to radionuclide
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labelling for nuclear imaging, although the approach generally is limited to the la-
belling of larger biomolecules where the size of the fluorophore does not interfere with
the biological activity of the agent. Again, fluorophores that are excited and emit
in or close to the optical window are preferred for good penetration depth and large
amplitude signals [6]. Table 2.3 provides data on a number of fluorophores that are
being used for in vivo studies and an example of a study carried out with a near
infrared fluorescence probe is shown in figure 2.3.
Name Type of agent
Excitation Emission Extinction coefficient Quantum
max (nm) max (nm) (cm−1 M−1) yield
Cy 5 Fluorophore 649 670 250000 0.28
Cy 5.5 Fluorophore 675 694 190000 0.23
Cy 7 Fluorophore 743 767 200000 0.29
Alexa Fluor 700 Fluorophore 702 723 192000
Alexa Fluor 750 Fluorophore 749 775 240000
EGFP Fluorescent protein 489 508 55000 0.60
DsRed Fluorescent protein 558 583 57000 0.79
mRFP1 Fluorescent protein 584 607 44000 0.25
Table 2.3: Properties of some fluorophoresa and fluorescent proteins. (Data for DsRed and
mRFP1 from [26]. Other data from manufacturers’ datasheets [6].)
There are two key advantages to fluorescence imaging. Firstly, many of the flu-
orophores used have high quantum yields, leading to robust signals when using ap-
propriate illumination and acquisition times. Secondly, as described earlier, the flu-
orescence emission can be activated by specific biologic molecules or events. This
eliminates signal from contrast agent that is circulating and from paths of excretion
(a limiting problem for radiotracers), reducing background “noise”. This allows very
low concentrations (subnanomolar, and with some activatable agents, picomolar or
better) of enzymes to be detected. The disadvantage of fluorescence imaging is that
there is autofluorescence from tissue that forms a background that ultimately limits
detection sensitivity. A second problem is that light has to get into the animal (to
excite the fluorescent molecules) and back out again (to reach the detector). Because
of the high degree of scattering of both the excitation and emission light, it is not
possible to excite and isolate the fluorescence within very small volumes of tissue
inside the animal. As a consequence of the strong dependence on depth of both the
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intensity of the excitation light and the detection of the emission light, quantitative
analysis of the images, in all but the very simplest cases of a small point emitter,
becomes extremely difficult [6].
Fluorescence imaging can be carried out using conventional CCD cameras. The
use of back-illuminated CCDs and cooling, enhances sensitivity and signal-to-noise
ratio, but for many studies general purpose scientific CCD cameras are sufficient,
because detection sensitivity is limited by autofluorescence rather than by the noise
characteristics of the detector. A simple black box and a lens coupled CCD camera
connected to a computer can yield acceptable fluorescence images showing the light
distribution on the surface of the animal in just a few seconds or minutes [28].
The second approach to in vivo optical imaging involves introducing reporter genes
that encode for enzymes (known as luciferases) that can catalyze a light-producing
reaction. This process is called bioluminescence and luciferases are found in organisms
such as fireflies, glow worms and jellyfish [29]. The most commonly used reporter gene
for imaging is the one that encodes for firefly luciferase [30]. This gene is introduced as
a reporter gene. Just prior to imaging, animals are injected with the substrate for the
enzyme. In the case of the firefly luciferase the substrate is luciferin, a small molecule
that rapidly distributes throughout the whole body of the mouse after intravenous or
intraperitoneal injection. In cells that are expressing the luciferase reporter gene, the
luciferin, in the presence of oxygen and ATP (Adenosintriphospat), is converted to
oxyluciferin with the emission of light (peak at 560 nm). The reaction is catalyzed by
the luciferase enzyme and does not occur to any significant extent when luciferase is
absent. The generation of an optical signal is therefore specific to cells that contain
the reporter gene. Mutations of the naturally occurring firefly gene has resulted in
a shifting of the emission peak to around 620 nm, with significant amounts of light
being emitted in the 550-700 nm range, improving its sensitivity for in vivo imaging
studies [22].
The advantage of the bioluminescence approach is that there is no need for ex-
ternal light stimulation. There is no problem, therefore, in depth of penetration of
the excitation light as there is with fluorescence, and there is no autofluorescence
background to contend with. The disadvantage is that this approach is limited to
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studying genetically manipulated cells or transgenic mice, or infectious agents such as
bacteria and viruses, as the reporter gene has to be introduced to the organism that
is to be studied. Also, the bioluminescence signals are typically very weak. These low
signals require the use of high quantum efficiency CCDs that are cooled to minimize
dark current over the integration time required to obtain an image (typically a few
minutes) [6].
The biggest efforts in optical imaging at the present time are devoted to moving
from a single image of the light intensity projected at the surface of the animal to
tomographic images that provide information on the distribution of the light source
in 3D. This involves acquiring data from a small number of views such that the light
intensity across the surface of the entire mouse can be mapped.
Figure 2.3: In vivo bioluminescence images (in colour) from cancer cells carrying a luciferase
reporter gene. These images show the growth of a pituitary tumour over a period of four
weeks. The greyscale image is a reflectance light image of the mouse for anatomic reference
[6].
2.2.3 Magnetic resonance imaging
Magnetic Resonance Imaging (MRI) is one of the more mature technologies for small
animal imaging. Magnetic resonance microscopy (generally defined as imaging with
a resolution of better ∼ 100 microns) has been around since the mid 1980s and has
found particular applications in neuroscience [31,32] and developmental biology [33].
High-field magnets are introduced in small-bore animal imaging systems several years
before they can be achieved for larger bore human applications. Therefore these ani-
mal systems serve as important test-beds and catalysts for developing high resolution,
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high speed and high sensitivity pulse sequences. Most small-animal imaging is cur-
rently carried out on horizontal-bore instruments with field strengths between 4.7
T and 9.4 T and bore sizes of 20-40 cm. Research systems with field strengths as
high as 11.7 T (40 cm horizontal bore) and 21.1 T (8.9 cm vertical bore) are also
being evaluated for small-animal imaging [34]. Higher field strengths are desirable
for high-resolution imaging because the signal-to-noise ratio (SNR) is proportional to
field strength, and the detected signal is proportional to the tissue volume within a
voxel. A reduction in voxel size from 1 × 1 × 1 mm to 0.1 × 0.1 × 0.1 mm therefore
results in a 1000-fold reduction in the detected signal.
Since SNR is only linearly proportional to field strength, higher fields only in part
make up for the reduced voxel size in high resolution images. Therefore, images at
resolutions of tens of microns can only be achieved with very long acquisition times,
typically many hours for a whole mouse.
In vivo images of anatomy with a spatial resolution of a few hundred microns can
be achieved in several minutes with MRI when combined with appropriate physiologic
gating to control cardiac and respiratory motion. Sophisticated physiologic monitor-
ing and forced respiration systems have been developed to allow motion-free in vivo
imaging and well controlled physiologic status deep inside a high-field magnet [35].
The good soft-tissue contrast achieved by well-designed pulse sequences has led to
MRI becoming the method of choice for following anatomic changes in soft tissue
that may be related to a disease course or an intervention. Furthermore, MRI has
the ability to measure physiological parameters, including water diffusion and blood
oxygenation levels (which leads to the contrast used in functional MRI to study brain
activation). The addition of “passive” contrast agents, such as Gd-DTPA, further en-
hances the utility of MRI, allowing vascular density, permeability and perfusion to be
assessed. Another example of a passive agent is the use of Mn2+ ions for tract-tracing
studies in the brain [36].
Taken together, these MRI methods provide a powerful set of tools for interro-
gating anatomic and physiologic changes that are a consequence of specific cellular
or molecular alterations in living animals. Of more interest is the development of
targeted and activatable contrast agents for MRI that offer the prospect of direct
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molecular imaging. These agents are based on transition metals or lanthanides that
are paramagnetic and change the relaxation time (either T1 or T2) in tissue regions
in which they accumulate [37].
One area of active research is into optimal RF coil design for high-field use. Design
of better volume coils should improve SNR and allow imaging of an entire animal
in significantly shorter times. High-powered imaging gradients with fast switching
rates for small-volume imaging have also improved the ability to acquire fast images
at higher signal-to-noise, and further improvements in the gradient coils are also
likely [6].
2.2.4 X-ray computed tomography
In vivo imaging of small animals with CT has a critical role to play in the evolution
of molecular imaging [38, 39]. The conventional anatomic CT with non-specific con-
trast agents is a relatively straightforward way to obtain high-resolution anatomic
information which is often important to analyze molecular imaging studies obtained
using other modalities (especially nuclear and optical approaches). MicroCT is also
a valuable tool for indirect approaches to molecular imaging [38], for example, imag-
ing changes in vascular density and permeability associated with angiogenesis and
anti-angiogenic therapeutics. MicroCT is the method of choice for tracking changes
in diseases that affect bone. The high resolution of microCT allows very sensitive de-
tection of bone growth, destruction, remodelling and changes in bone density, and is
therefore ideally suited for studying the consequences of diseases such as osteoporosis
and rheumatoid arthritis, and for evaluating the effects of therapeutic interventions
on the progression of these diseases [6]. MicroCT also has the potential to be used as
a fairly high-throughput imaging technique and investigators are considering its use
for phenotypic screening in genetically manipulated mice [40].
Some of the specific and continuing challenges in moving from specimen imaging
to in vivo imaging have been to reduce the radiation dose, deal with motion artefacts,
change the system geometry to allow the animal to be placed horizontally and remain
stationary during scanning and to decrease imaging time.
To date, microCT systems have made use of 2D x-ray detectors developed for
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specimen imaging or digital mammography, and systems generally acquire data in
cone-beam geometries. This imaging geometry is relatively simple to implement
and the 3D collection makes the most efficient use of the relatively modest x-ray
flux that is emitted by the compact microfocus fixed anode x-ray tubes generally
employed in these applications [41]. These low-power tubes are supported by compact
power supplies and the small x-ray focal spot size offers the potential for very high
spatial resolution. At the same time, the anode current (and hence number of x-rays
produced) of these compact tubes is limited by the small focal spot size and the
fixed anode design when operated continuously for CT acquisition. Typical x-ray
tube parameters used in microCT systems are focal spot sizes in the range of 10-100
microns, and tube currents of at most a few mA at an anode voltage of 25-75 kV. Most
commonly, tungsten anode tubes are being utilized. For CT imaging, the x-ray tube
is generally operated continuously with a shutter to control when x-rays irradiate the
object. A resolution of tens of microns is achievable in some microCT systems [6].
2.2.5 Ultrasound
Ultrasound also has been successfully adapted as a tool for small animal imaging
and together with the development of novel echogenic contrast agents promises to
add molecular imaging capability in a number of very important areas. Advantages
of ultrasound include real-time imaging, portability, low cost, high spatial resolution
and the absence of ionizing radiation. One of the key trade-offs in ultrasound is
between acoustic frequency, depth of penetration, and spatial resolution. In small-
animal models, a depth of penetration of 1-2 cm is generally sufficient, allowing high
frequencies on the order of 20-60 MHz to be used. This leads to a spatial resolution
in the range of tens of microns [6]. One of the really unique capabilities of ultra-
sound is in developmental studies [42], particularly pre-natal studies in genetically
manipulated mice (see figure 2.4). Genetic manipulations often result in embryonic
lethal phenotypes that do not survive to birth, hence the ability to determine phe-
notypes in utero is extremely important. High-resolution embryonic imaging cannot
be performed noninvasively with any other modality at the present time due to fetal
motion, which requires very fast acquisition. The real-time nature of ultrasound is
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also of importance in studying cardiac anatomy and function in rodents, and opens
up opportunities for image-guided interventions in animal models.
The capabilities of ultrasound go far beyond anatomic imaging for phenotypic
analysis. High frequency Doppler flow mapping enables quantitative measurements of
blood flow not only in major vessels, but importantly, also in the microcirculation [43].
Contrast agents are being developed that promise to give ultrasound a major role in
molecular imaging and therapeutics [44, 45]. In their simplest form, these contrast
agents are small bubbles (typically 1-10 microns in diameter) in which a lipid or albu-
min shell is filled with a gas such as perfluoropropane. These microbubbles produce
very strong ultrasound echoes due to differences in their compressibility and den-
sity compared to surrounding biologic tissues. In fact a standard clinical ultrasound
system can detect the echo from an individual microbubble, thus in principle, the
sensitivity for detection of such contrast agents is extremely high. Microbubbles are
already in clinical use, where they are used to detect small vessels and capillary beds
by enhancing the signal from the small volume of blood. In addition, microbubbles
have interesting non-linear oscillation properties in response to ultrasound radiation.
With appropriate acoustic pressure, these bubbles can actually burst. By applying
local acoustic pressure to burst the bubbles, the contrast agent can be selectively
destroyed within a small volume of tissue. By imaging the return of the signal as
blood containing intact contrast agent flows into the region, it is possible to quantify
important physiologic parameters such as blood velocity, blood flow and blood vol-
ume in the microvasculature. These measurements can be repeated over and over for
a single contrast agent injection with high spatial and temporal resolution [6].
2.3 General requirements for molecular imaging
The acquisition of ex vivo information in biomedical research has become relatively
easy, because a myriad of specialty reagents, ligands, protocols, and devices have been
commercially developed over the past two decades. On the other hand, molecular
imaging in living subjects presents more theoretical and practical challenges than
in vitro or cell culture detection, primarily because of the need for probes to be
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Figure 2.4: High frequency (40 MHz) ultrasound image of a 13.5-day-old mouse embryo.
The resolution in this image is better than 100 microns. (Adapted with permission of World
Federation of Ultrasound in Medicine and Biology from [46]).
biocompatible, the presence of additional delivery barriers, and the necessity for
developing special in vivo amplification strategies [47]. There are several general areas
in which considerable research efforts are ongoing [11,28] and will also be necessary in
the future to perform in vivo molecular imaging (by seeking answers to the questions
in parenthesis) [1]:
• selection of appropriate cellular and subcellular targets to image (what biolog-
ical process is to be imaged?).
• development of suitable in vivo affinity ligands, that is, molecular imaging
probes (what biocompatible chemical/biochemical/ molecular entity can be
used in vivo to distinguish that particular biological process and help to gener-
ate specific images of that target?).
• delivery of these probes in a manner that efficiently overcomes biological bar-
riers (what are the pharmacokinetic attributes of these probes contributing to
successful imaging?).
• amplification strategies able to detect minimal target concentrations, usually in
the pico-to nanomolar range (can the imaging signal be amplified?).
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• development of imaging systems with high spatial/temporal resolution and sen-
sitivity suitable for small laboratory animals, and that ultimately can be trans-
lated to the human patient (what are the imaging modalities and instrumenta-
tion available to achieve molecular imaging in living subjects?)
2.4 Specific applications of PET molecular imaging
The use of either of PET or SPECT in small animal biological research has the ad-
vantage that essentially the same methodology can be used in human applications,
thereby facilitating translation to the clinic. The classical example of a transla-
tional research application in molecular medicine is the introduction of STI- 571
(Gleevec R©), a small molecule designed to alter specific intracellular signalling path-
ways involved in cell proliferation and apoptosis, which lead to chronic myeloid
leukaemia [48]. STI-571 specifically inhibits the oncogenic protein tyrosine kinase
breakpoint cluster region (BCR)Abelson (ABL), which is constitutively activated by
a chromosomal translocation.
Some PET molecular imaging specific applications are reported.
2.4.1 Glucose metabolism in brain and heart
The probe of excellence in PET studies of metabolism is 2-deoxy-2-[18F]fluoro-D-
glucose (FDG). It is transported into cells by the glucose transporter and subsequently
converted to the phosphorylated form by hexokinase. FDG-6-phosphate, the product
of hexokinase, cannot be further metabolized and is “trapped” inside cells, where its
accumulation can be measured in the PET scanner.
In the latest generation of small animal PET systems, the spatial resolution is
sufficient (<2 mm) to clearly identify structures such as the thalamus, striatum, and
cortex subunits and to separate extracerebral activity from cerebral activity in the
adult rat. A range of semiquantitative investigations of brain plasticity and conscious
brain activation have been performed [49] and a series of fully quantitative longitu-
dinal studies in a traumatic brain injury model, complete with direct comparison to
quantitative 2DG autoradiography [50], have also been reported. Even at this resolu-
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tion, though, there is a problem with brain FDG studies in small rats and mice, due
to spillover of activity from the Harderian glands into the cortex. The same spillover
problem has been reported in adult rats as well, but with poorer resolution tomo-
graphs [51]. Small animal PET scanners are also being employed to measure glucose
metabolism and myocardial blood flow (with 13N-ammonia) in rat and mouse heart
models of ischemia and infarction. Initial investigations comparing infarct extent [52]
and FDG uptake [53] against in vitro measures are promising. The group at Sher-
brooke University and Prof. Markus Schwaiger of the Nuklearmedizinische Klinik
und Poliklinik der Technischen Universitat Munchen, Munich, Germany have also
demonstrated the feasibility of acquiring gated PET images of the rat heart [54, 55].
2.4.2 Dopaminergic system in rat brain
Some of the earliest small animal PET work used a variety of probes to explore the
dopaminergic system in the rat brain. Probes that reflect dopamine synthesis (e.g.,
18F-fluoro-metatyrosine, 18F-FDOPA), D2 receptor binding (e.g., 11C-raclopride, 18F-
fluoroethylspiperone), and dopamine transporter concentration (e.g., 11C-CFT) are
available [10]. These probes are accumulated to a high degree in the striata, which are
fairly large and well separated in the rat brain. Therefore, successful investigations
can be performed even at moderate 3- to 4-mm spatial resolution [56]. This work
demonstrated, for example, the ability of PET to quantify D2 receptor in the living
rat brain [57], the survival and function of neural transplants [58–60], and the effects
of drugs on D1 and D2 receptors [61, 62]. An example from one of these studies is
shown in figure 2.5.
2.4.3 Oncology
Some of the best opportunities for small animal PET imaging are in oncology. Study-
ing transplanted primary tumors is often simple since they can be placed away from
major organs in the thigh, shoulder, or back of the animal. Under these circum-
stances, corrections for partial volume are straightforward. In addition, the usual
variability between one animal and the next is effectively removed and each animal
can be used as its own control. Furthermore, PET can survey the entire animal and
26 Chapter 2. The role of preclincal imaging
Figure 2.5: Coronal section through rat brains showing D1 and D2 receptor binding fol-
lowing injection of 11C-SCH 23390 and 11C-raclopride respectively. Four different rats are
shown: control rat; lesioned rat (unilateral ibotenic acid lesion); lesioned rat following graft
of striatal cells from 15-mm crown to rump fetuses; lesioned rat following graft of striatal
cells from 10-mm crown to rump fetuses. Rats with grafts were scanned approximately
10 months post surgery. Note: Loss of D1 and D2 binding signal on right side of image
following lesion and partial recovery of the signal in the rat that received a striatal graft [10].
allows the spread of metastatic disease to be observed and monitored [10]. There
is a range of PET probes that are of interest in cancer models, including FDG,
3’-deoxy-3’- [18F]fluorothymidine (FLT), a marker of DNA replication and cell pro-
liferation [63], and labeled antibodies and antibody fragments [64]. The power of
serial PET investigations as a tool for assessing the time course and localization of
antibody fragments is demonstrated in Figure 2.6, which illustrates a mouse imaged
using an anti- CEA minibody, a genetically engineered antibody fragment that binds
with high affinity to carcinoembryonic antigen [65].
2.4.4 Reporter gene expression imaging
The merger of molecular imaging with molecular biology to create methods to mea-
sure reporter gene expression in vivo with PET is an area that has attracted increasing
interest. In analogy with the way Green Fluorescent Protein (GFP) is used as a stan-
dard reporter gene in molecular biology [66], a PET reporter gene (PRG) expresses a
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Figure 2.6: Coronal PET image of a mouse injected with a radiolabeled anti-CEA minibody,
a genetically engineered antibody fragment that binds with high affinity to carcinoembryonic
(CEA) antigen. The minibody was radiolabeled with the positron emitter 124I and used
for microPET imaging of LS174T tumor xenograftbearing mice. The mouse shown had a
73-mg tumor on the left shoulder, and was injected with 60 Ci of 124I anti-CEA 18 h before
imaging. Note the absence of anatomical landmarks besides the faint mouse outline. The
engineered antibody fragment (minibody) is also illustrated [10].
protein that can trap or bind a positron-labeled probe [67–72]. These are called the
PET reporter probes. The reporter gene is driven by the same promoter as the gene
of interest (the promoter can be thought of as a “switch” that turns the expression of
the gene on or off), such that the gene of interest is always expressed along with the
reporter gene. The retention of the positron-labeled probe by the protein product of
the PRG has been shown to be proportional to the level of reporter gene expression.
In turn, this reflects the level of expression of the gene of interest, which has the
same promoter or is coupled directly to the PRG (i.e., PRG coupled to a therapy
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gene) [73]. In this way, the location, magnitude of expression, and time course of
expression levels of any gene that is introduced into a mouse can be monitored in
vivo. This allows gene therapy protocols to be monitored in vivo, both in animal
models and, ultimately, in humans by PET. The same PRG approach can be used
in transgenic mice, where every cell in the mouse carries the PRG. In this case, the
signal is only detected when the promoter driving the PRG is switched on in the nat-
ural location where specific genes are expressed. This now enables endogenous gene
expression to be investigated in mice models [74]. Figure 2.7 is an image of a mouse
bearing two tumors, each expressing a separate reporter gene, namely the HSV1-tk
gene and the dopamine type 2 receptor (D2R) gene. The mouse was injected in two
different instances with two different reporter probes, 3-(2’-[18F]fluoroethyl)- spiper-
one (FESP) and 8-[18F]fluoropenciclovir (FPCV), each probe being specific for one
of the gene reporter systems. The image shows clearly the selectivity of the reporter
probes in each tumor [75].
Figure 2.7: Image of a mouse bearing two tumors, each tumor expressing a different reporter
gene. The one on the right carries the HSV1-tk reporter gene and the one on the left, the
D2R reporter gene. The mouse was injected with two different reporter probes, FESP and
FPCV, on two separate days. Each probe was specific for one of the gene reporter systems.
The image shows clearly the selectivity of the reporter probes in each tumor. Background
activity is seen from routes of clearance of tracer, which are renal and gastrointestinal [10].
Chapter 3
Radioprotection issues in
PET/SPECT imaging
Radiation is naturally present in our environment and has been since the birth of
this planet. It comes from outer space (cosmic), the ground (terrestrial), and even
from within our own bodies. It is present in the air we breathe, the food we eat, the
water we drink, and in the construction materials used to build our homes. Certain
foods such as bananas and brazil nuts naturally contain higher levels of radiation
than other foods. Brick and stone homes have higher natural radiation levels than
homes made of other building materials such as wood. Consequently, life has evolved
in an environment which has significant levels of ionizing radiation [76].
However, it has been recognized since early studies on X rays and radioactive
minerals that exposure to high levels of radiation can damage the tissues of the
human body. In addition, long term epidemiological studies of populations exposed to
radiation, especially the survivors of the atomic bombing of Hiroshima and Nagasaki
in Japan in 1945, have demonstrated that exposure to radiation also has a potential
for the delayed induction of malignancies. It is therefore essential that activities
involving radiation exposure, such as the production and use of radiation sources
and radioactive materials, and the operation of nuclear installations, including the
management of radioactive waste, be subject to certain standards of safety in order
to protect those individuals exposed to radiation [77].
Performing PET and SPECT imaging presents radiological hazards due to the
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use of radioactive isotopes that create ionizing radiation, with half lives ranging from
minutes to days.
3.1 Basic principles in radioprotection
Radiation exposure limits or standards were introduced as early as the start of the
20th century when the potential hazards of radiation were realized. One of the first
standard-setting bodies was the International Commission on Radiological Protection
(ICRP), which continues its function through its series of publications. These reports
form the basis for many national protection guidelines [78]. It is exactly in the ICRP
Publication #60 [79], that ICRP defines a system of dose limitation based on three
principles:
• Justification of the practice: no practice shall be adopted unless its intro-
duction produces positive net benefit.
• Optimization of the protection: all exposure shall be kept as low as rea-
sonably achievable considering the economic and social factors. This principle
is known also as ALARA (As Low as Reasonably achievable) principle.
• Dose limit: the dose equivalent to individuals shall not exceed the limits
recommended for the appropriate circumstances by the Commission.
The term practices refers to all the human activities that add radiation exposure
to that which people normally incur due to background radiation, or that increase
the likelihood of their incurring exposure [77].
The three ICRP principles have been completely acknowledged by the Italian
Law Decreto Legislativo 230 of the 1995 (D.Lgs. 230/95) and by the subsequent
modifications and integration (s.m.i.), in particular by the Decreto Legislativo 241
del 26 Maggio 2000 (D.Lgs. 241/2000) [80] that acknowledges the European disposal
EURATOM 29 of the 1996 [81].
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3.2 Law provisions
According to the D.Lgs. 230/95 and s.m.i., every times a new practice employing ra-
dioactive sources is introduced or extended, a specific authorization must be required.
The authorization request has to be presented to authorities.
The Italian legislation foresee to get informed the following authorities: A.S.L.
Dipartimento di prevenzione, Comando provinciale dei vigili del fuoco, A.R.P.A. and
the Direzione Provinciale del lavoro. A radioprotection report reviewed by a Qualified
Expert, in which the level of exposure, the risk for the workers and the public and
the eventual shielding required are reported, must be prepared.
For the purposes of radiation protection, ionizing radiation exposures are divided
into three types [82]:
• Medical exposure, which is mainly the exposure of patients as part of their
diagnosis or treatment.
• Occupational exposure, which is the exposure of workers incurred in the
course of their work, with some specific exclusions.
• Public exposure, which comprises all other exposures of members of the pub-
lic that are susceptible to human control.
3.2.1 Dosimetric quantities
The quantities in which the dose limits are expressed are the equivalent dose (HT )
and the effective dose (E) in tissue or organ T [80]. The effective dose is generally
considered to be an adequate indicator of the health detriment from radiation ex-
posure at the levels experienced in normal operations. A limit on equivalent dose is
needed for skin and the lens of the eye in order to ensure the avoidance of determin-
istic effects in these tissues. The protection quantities E and HT relate to the sum of
the effective or equivalent doses received from external sources within a given time
and the committed effective or equivalent doses from intakes of radionuclides that
occurred within that time [82]. The equivalent dose HT,R in the tissue or organ T
due to the radiation R is expressed by equation 3.1:
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HT,R = wR ·DT,R (3.1)
where:
• DT,R is the average absorbed dose in the tissue or organ T due to radiation R;
• wR is the weighting factor for the radiation R. This factor assumes the value 1
for X-rays, γ and electrons, 5 for protons, a value in the range 5-20 for neutrons
according to their energy and 20 for α particles or heavy ions.
The effective dose E (see equation 3.2) is defined as the sum of the weighted
equivalent doses in the body tissues and organs due to both internal and external
radiation:
E =
∑
T
wR · HT =
∑
T
wT
∑
R
wT ·DT,R (3.2)
where:
• HT is the equivalent dose in the tissue or organ T;
• wT is the weighting factor for the the tissue or organ T;
• wR is the weighting factor for the radiation R.
• DT,R is the average absorbed dose in the tissue or organ T due to radiation R.
Both HT and E have the same unit of measurement of the absorbed dose, namely
joule per kilogram, but the name sievert (Sv) is used in order to avoid confusion with
the unit of absorbed dose (Gy).
The total effective dose ET received or committed during any time period t can
be estimated from the equation 3.3:
E = ET +
∑
j
h(g)j,ingJj,ing +
∑
j
h(g)j,inaJj,ina (3.3)
where:
• ET is the effective dose due to external exposition in the tissue or organ T;
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• hj,ing and hj,ina are the dose coefficients for, respectively, ingestion and inhala-
tion of radionuclide j by age group g;
• Jj,ing and Jj,ina are the intakes, via ingestion and inhalation respectively, of
radionuclide j during time period t.
3.2.2 Dose limits and areas and workers classification
A dose limit is defined as “The value of the effective dose or the equivalent dose
to individuals from controlled practices that shall not be exceeded. The limits on
effective dose for occupational exposure apply to the sum of effective doses from
external sources and committed effective doses from intakes in the same period” [77],
according to the equation 3.3.
The limits on effective dose (E) for occupational exposure is fixed to 20 mSv per
year or an equivalent dose (HT ) to the lens of the eye of 150 mSv in a year or an
equivalent dose to the extremities (hands and feet) or the skin of 500 mSv in a year.
The equivalent dose limits for the skin apply to the average dose over any skin surface
of 1 cm2. The effective dose limit for public exposure is 1 mSv per year. To this limit
do not contributes neither the natural radiation nor the cosmic rays (see figure 3.1).
Figure 3.1: Left: average yearly global radiation dose from all sources of radiation. Right:
radiation dose from cosmic rays.
The occupational exposure classifies the personnel according to the possibility or
the risk to exceed one of the limits reported in Table 3.1.
Whenever there is occupational exposure to radiation working, areas must be
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Exposed personnel Exposed personnel Non occupational
Category A Category B (Public)
Effective dose 6 mSv 1 mSv < 1 mSv
Equivalent dose to 45 mSv 15 mSv < 15 mSvthe lens of the eye
Equivalent dose 150 mSv 50 mSv < 50 mSvthe extremities
Table 3.1: Radition dose limits for not exposed people (Public) and for exposed personnel.
classified. A classified area is one where there is a need to adopt procedural controls
to ensure an optimized level of protection and compliance with the relevant dose
limits. Two types of area may be defined: controlled and supervised areas.
In a controlled area the following requirements must be fulfilled:
– the access is signaled and regulated;
– there is the risk to exceed the dose limit for Exposed personnel in Category A;
– it is required the periodic environmental control performed by the Qualified
Expert and the dosimetric control of the classified personnel.
In a supervised area:
– the access is signaled;
– there is the risk to exceed the dose limit for the Public.
3.3 Hazards of employed sources
As reported in section 3.2, when dealing with radiation hazards, two different expo-
sition processes must be taken in account: external and internal radiation. Each of
which has a different hazard degree depending on the radiation type [83]. In fact,
X-ray, γ, β, e− and neutron emissions lead to exposures depending on the nature and
energies of the corresponding radiation as well as the packaging and geometry of the
source [84].
PET imaging employs β+ emitters, whose positrons undergoes annihilation with
electrons and produce two photons having identical energy (511 keV) and emitted
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simultaneously, in 1800 degrees opposing directions. Thus concerning radiation pro-
tection, we are dealing with gamma radiation of 511 keV energy.
SPECT imaging employs γ emitters of variable energies ranging from ∼ 30 keV
of the 125I to more than 300 keV of 125I. For radioprotection issues, it must be taken
in account, that a few SPECT tracers, like 99mTc have also a β− or electron emis-
sion. Besides, it must be considered that in PET/SPECT imaging both sealed and
unsealed sources can be employed. The sealed sources are point-like, linear or planar
solid sources usually employed during calibration procedures. While unsealed ones
are liquid sources that can be employed for both scanner calibration and in vivo
experiments.
Electron radiation can be a radiobiological hazard for both external or internal
radiation. In the external radiation two processes can be distinguished: the direct or
Bremsstrahlung radiation. In the direct radiation, the electrons can be easily shielded
by a few millimeters thick material. In the Bremsstrahlung radiation, the shielding
used to stop the direct β− radiation can itself produces X-rays due to bremsstrahlung.
This radiation can be reduced by using shielding materials with low atomic number
(Z).
X and γ radiation. The X and γ hazards are directly connected with their high
penetration capabilities in both air and living tissues. About internal radiation, the
high penetration power of X and γ rays is an advantage. In fact, the energy released
to the tissues is distributed in a bigger volume, so the released energy per unit of mass
(dose) is lower respect to charged particles like electrons. On the contrary, external
radiation photons presents a high hazards since in air they can propagate far from
the source without or with low attenuation (the mean free path of a 511 keV photon
is about 100 m in air [85]). Shielding realized with thicker and with high Z materials
are then necessary compared to electrons shieldings.
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3.4 Physics principles to minimize external radiation
exposure
There are three principal methods by which external radiation protection can be
minimized:
• time
The absorbed dose of an organism exposed to radiation is directly proportional
to the exposition time, then reducing the time spent near a radiation will reduce
one’s radiation exposure. The time reduction can be achieved by having a
thorough understanding of the tasks to be performed, i.e., it is worthwhile to
have practiced the steps to perform with the source with a non-radioactive
substance so to learn how to better proceed.
• distance
The exposure rate from a point source of radiation (i.e., a source whose physical
dimensions are much less than the distance from which it is being measured)
decreases as the distance from the source squared [86].
• shielding
The decision to utilize shielding, and its type, thickness and location of a par-
ticular application are functions of the photon energy, intensity and geometry
of the radiation sources and exposure rate goals at various locations.
3.5 Considerations for safe radioisotopes and animal
handlings
In performing PET/SPECT imaging both external and internal radiation hazards
are present. Thus, safely practices from radiotracers handling to storage aspects, and
from delivery to final disposal are necessary to reduce the potential risks.
To this aim the following considerations are addressed on radiotracers handling
and storage aspects, from delivery to final disposal.
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• Personal protective equipment and clothing
To minimize the potential for personnel contamination personal protective equip-
ment and clothing have to be worn, including laboratory coat, gloves and shoe
covers.
• Eating and drinking
To minimize intake of radioactive material by personnel, eating or drinking,
including chewing gum or smoking, should not be permitted in contamination
areas [87].
• Delivery of radioactive compound
Receiving and storing areas are necessary. If the cyclotron is close to the
PET/SPECT imaging laboratory, a thick lead container (called “lead pig”) con-
taining the vial with the desired activity can be appropriate for dose transporta-
tion (see figure 3.2), while a shielded hood or lead shield configuration can be
suitable for dose storage (see figure 3.3). On the contrary, when the radiotracers
is purchased by an external company, it is supplied in a heavy transportation
box (usually 25 kg or more, i.e. see figure 3.3). Given the weight of the trans-
portation box, sufficiently strong dollies are recommended to transport the box
from the receiving point to the storage place.
• Dose preparation
Once safely stored in a shielded area, the radiotracer needs to be dispensed
using a dose calibrator (see figure 3.4). A lead shielding configuration is often
used in combination with an L-shaped shield and lead glass window for dose
dispensing. A dose carrier, either lead or tungsten, can be used to transport
the dose to the injection area. Once injected, the syringe can be assayed for
residual activity and disposed of in a shielded sharps container (see figure 3.2).
The vial or syringe with the bulk dose can be held until no longer radioactive
before disposal.
• Animal radiotracer injection
The injection site varies depending on the species, probe, and experimental
design. Rats and mice can be injected via intraperitoneal (ip), tail vein (iv)
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or using surgically implanted catheters. For mice, most often either ip or tail
vein injections are used. Using a large and heavy shielding cover on the syringe
makes injections nearly impossible, so usually the syringe is used quickly with
no shielding for injections. An experienced person can inject either ip or iv
in only a matter of a few seconds; thus, radiation protection is accomplished
using the shortest possible exposure time. Another alternative is to first place
a catheter in the blood vessel, reducing the radioactivity handling time to a
minimum of just making the tubing connection and injection [88].
• PET/SPECT imaging
Once injected, the animals are radioactive and need to be kept away from
personnel if possible. During imaging, typically shielding is not an option, so
the imaging systems ideally should be located away from where people are likely
to sit or stand. After imaging, animals can be put back into cages and kept in
a shielded location (see figure 3.5).
• Post-scan requirements
Once the experiment is over, the animal, cage, bedding material, and any ab-
sorbent padding used for imaging, along with any urine or feces should be
considered radioactive and disposed of accordingly (see figure 3.4). For short-
lived isotopes, the trash can be held overnight or until surveyed and verified as
no longer radioactive before disposal. If longer-lived isotopes are planned for
use, consideration of where wastes and cages can be stored is necessary.
• Storage of radioactive animals
Storage of radioactive animals may need to be considered, as vivarium personnel
are often not trained as radioactivity workers nor is it wise to expose other
animals or personnel in the vivarium to radioactivity. Fortunately, the amount
of radioactivity required for imaging and the often short half-life mean that
there is very little activity in most animals when they are returned to the
vivarium. For PET/SPECT experiments, activity levels are low enough that
radioactive animals can be stored in a dedicated radioactive cabinet located
within the main vivarium room, or perhaps in a separate room (see figure 3.5).
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• Monitoring workers for personnel contamination
Personnel should wash their hands and check for contamination with a large
area proportional counter or a thin window GM counter every time exiting from
a potential contaminated area to an uncontaminated one.
Figure 3.2: Photo of the chemical hood within the scan room.
Figure 3.3: Photo of transportation box (left) and zoom of the lead pig (right) [89].
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Figure 3.4: Photo of dose calibrator(left) and of the radioactive waste container within the
scan room.
Figure 3.5: Photo of the ventilated cabinets inside the storage room (left) and scan room
(right).
3.6 Shielding requirements
The shielding of PET/SPECT laboratory presents special challenges. In fact, because
of the high penetration of 511 keV annihilation photons (see section 3.3) and the re-
latively long half life of SPECT radioisotopes, all surrounding areas in the vicinity
of the PET/SPECT laboratory must be considered for shielding calculations. As a
result, barrier shielding may be required in floors and ceilings as well as adjacent
walls. Besides, since the animal becomes the radioactive source after the radiophar-
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maceutical has been administered, one has to consider the entire time that the subject
remains in the laboratory.
In determining the amount of required shielding, several factors have to be taken
in account:
• the workload (W).
• The use factor (U).
• The occupancy factor (T).
• Regulatory dose limits (P).
• The transmission factor (B) across the barrier.
Workload
For both sealed and unsealed radioactive sources the exposure levels produced are
strictly related to the activity of the source and its decay scheme. Each radionuclide
is characterized by a dose rate constant (Γ) that, taking into account the numbers and
the type of the particles emitted by the source, supplies the exposure rate produced at
1 meter from the considered source, for unit of activity and time. The Γ measurement
units are [mSv ·m2 · h−1 · GBq−1] and its value is strongly dependent on the geometry
of the source and on the distance at which the exposure rate is calculated. Figure
3.6 reports the Γ values for several sources configuration for 18F.
Figure 3.6: Dose rate constant (Γ) for several sources configuration for 18F. Image repro-
duced from [84].
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Thus, a radioactive source of activity A and dose rate constant Γ produces, at 1
meter, the following dose rate:
D˙ = Γ · A (3.4)
Because of PET and SPECT half lives, the total radiation dose received over a
time period t, D(t), is less than the product of the initial dose rate and time [D˙(0)
× t]. The reduction factor, Rt, is calculated as:
Rt = D(t)/D˙(0)× t = 1.443× T(1/2/t)× [1− exp(−0.693 t/T1/2)] (3.5)
In determining the radiation dose to the surrounding areas, the injected animals
are the primary source of radiation that need to be considered. Therefore, it has to
be taken in account the number of animals imaged, the amount of radiotracer ad-
ministered per animal, the length of time that each animal remains in the laboratory
and the location of the laboratory.
The workload indicates the amount of dose produced over a defined working time,
i.e., the dose produced over a week or a year. Usually, the workload is evaluated per
week, but for specific needs it can also be computed per year. If Nw is the number of
animals imaged per week, A the amount of radiotracer administered per animal and
th the number of hours the animal remains in the laboratory, the weekly workload is:
W = Γ[mSv m2/MBq h]× A[MBq]× Nw × th[h]×Rt (3.6)
Equation 3.6 supplies the workload at 1 meter from the radioactive source, if the
workload at a point d meters from the radioactive source is requested, Wd is supplied
by:
Wd =
W
d2
(3.7)
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Use factor
The use factor, U, indicates the fraction of time during which the radiation under
consideration is directed to a particular barrier. Due to the isotropic nature of the
emitted radiation, for PET/SPECT radioisotopes, U is considered 1 in each direction.
Occupancy factor
The occupancy factor, T, indicates the average fraction of time over a predetermined
period of time (a week or a year) that a single individual might spend in an adjacent
area. If the room adjacent to the PET/SPECT laboratory has a permanent occupa-
tion, the occupancy factor T is 1, if the occupation is partial T = 1/4, and for an
occasional occupation of the room T = 1/16. Suggested occupancy factors are listed
in Table 3.2.
Occupancy factor Room utilization
T=1 Offices, waiting rooms, inhabited roomFull occupancy
T=1/4 Corridor, parkingPartial occupancy
T=1/16 Stairs, lift, street, lumber roomOccasional occupancy
Table 3.2: Suggested values for occupancy factor [86].
Regulatory dose limit
The dose limits in controlled radiation areas and uncontrolled areas open to the gen-
eral public are reported in section 3.2.2. Under these regulations, the PET/SPECT
laboratory must be shielded so that the effective dose equivalent in adjacent uncon-
trolled areas does not exceed 1 mSv/year or 20 µSv/week.
Transmission factor
The transmission factor, B, is the ratio between the shielding design goal modified
by the occupancy factor (P/T) and the output at distance d without shielding (W ·
U / d 2). Hence, B is:
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B =
P
Wd · T · U =
P · d2
W · T · U (3.8)
Shielding calculation
From the transmission factor B, it is possible to determine the shielding thickness in
terms of Tenth Value Layer (TVL or x1/10). The TVL is the thickness of homoge-
neous absorber that attenuates the radiation intensity I(0) of one tenth of its original
intensity, i.e.:
I(x1/10) =
1
10
· I(0) = I(0)e−µ·x1/10 (3.9)
resulting in:
1
10
= e−µ·x1/10 (3.10)
The equation 3.10 can be generalized for multi tenth-value layers:
1
10NTVL
= e−µ·NTVL·x1/10 (3.11)
Since e−µ·NTVL·x1/10 represents how much the radiation intensity I(0) is attenuate,
it is possible to express the transmission factor B as follow:
1
10NTVL
= e−µ·NTVL·x1/10 = B (3.12)
From which:
B =
1
10NTVL
(3.13)
And finally:
NTVL = − log(B) (3.14)
The lead thickness is simply obtained by multiplying NTVL for the corresponding
TVL of the radioisotopes under investigation.
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tPb = NTVL · TVL (3.15)
All this calculation consider only primary barriers.
Because the 511 keV annihilation photons are so penetrating, it is necessary to
consider uncontrolled areas above and below the PET facility as well as those adjacent
on the same level. Figure 3.7 shows generally accepted source and target distances
that apply in these cases. Typically, one assumes that the source of the activity is
1 m above the floor. The dose rate is calculated at 0.5 m above the floor for rooms
above the source, and at 1.7 m above the floor for rooms below the source [90].
Figure 3.7: Generally accepted source and target distances used for floor and ceiling barrier
calculation [90].
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Chapter 4
The set-up of the PET/SPECT
laboratory
This chapter deals with the set-up of the PET/SPECT laboratory realized in 2008
by the Molecular Biotechnology Center of the University of Torino within the Center
of Excellence in Preclinical Imaging (CEIP). In particular, it is described the radio-
protection plan prepared in collaboration with the Qualified Expert service of the
University of Torino lead by the Prof. C. Manfredotti with the assistance of Dr.
Mallamace and Dr. L. Visca.
The main issues concerning the radioprotection plan deals with:
• features of the employed sources.
• The selection of the rooms reserved for radioactive employing and the descrip-
tion of the equipment positioning.
• Shielding.
• Evaluation of the radiation exposure to both personnel and public.
• Management of the radioactive wastes and residuals.
• Classification of the areas and of the workers.
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4.1 The Center of Excellence in Preclinical Imaging
(CEIP)
The CEIP is located inside the Bioindustry Park Silvano Fumero S.p.A. (see figure
4.1) , a science and technology park located in Canavese, an area near Turin. Since
its creation in 1998, the Park has acted as system integrator for the development of
Life Sciences in the region [91].
The goal of CEIP is to offer to universities, research centers and companies know-
how and methodologies based on imaging techniques in order to facilitate and speed
up the process of development of new diagnostic and therapeutic solutions.
Figure 4.1: Photograph of the Bioindustry Park Silvano Fumero S.p.A. [91]
The CEIP is equipped with different imaging technologies such us MRI, PET-
SPECT, X-ray, optical imaging, ultrasound and it is coupled in a synergic way with
facilities and laboratories of different other companies located in Bioindustry Park
area including Bracco Imaging S.p.A. [92], Advanced Accelerator Application [89]
and Ephoran [93].
• MRI systems
– A clinical open, low field 0.2 Tesla (ESAOTE) system with dedicated coils
for imaging large animals (cats and dogs) and rodents.
– A 1 Tesla desktop MRI scanner (Icon, Bruker [94]) for small rodents like
rats and mice. The system consists of a 1 T permanent magnet (without
extra cooling required for the magnet) mounted on a 1.8 × 0.8 m table,
providing enough space for the operational electronics, an anesthesia sys-
tem, and a host computer. Its gradient coil provides 450 mT/m. The
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scanner’s fringe field is enclosed in the entire footprint of the 1T-MRI,
which is less than 2 m2.
– A preclinical 3 Tesla system (BioSpec, Bruker [95]) with a horizontal mag-
net (31 cm bore) equipped with two gradient bores (21cm and 11cm)
that provide a gradient coil strength of 200 mT/m 400 mT/m at 200 Am-
pere. The system has two transmitter and receiver channels for 1H, 13C,
and 19F imaging and two transmit and surface coils for imaging of small
(rats and mice) and large animals (rabbits).
– A preclinical 7 Tesla system (Pharmascan, Bruker [96]) with one gradient
bore (15 cm) that provides a strength of 300 mT/m and in which can be
inserted RadioFrequency (RF) coils for both mice and rats.
• Nuclear Medicine and X-ray systems
– the small animal YAP-(S)PET scanner (see chapter 5), a PET/SPECT
scanner produced by the small italian company I.S.E. Ingegneria dei Sis-
temi Elettronici s.r.l., Pisa, Italy. The peculiar architecture of the system
(four rotating heads mounted on the same gantry) allow to perform both
PET and SPECT acquisition and also simultaneous PET/SPECT ones.
– The SPECT/PET/CT trimodality system (Triumph, Gamma Medica [97].
The SPECT system utilizes solid-state cadmium zinc telluride (CZT) de-
tector technology. The PET system uses LYSO and LGSO scintillators
individually coupled to Avalanche Photo Diode (APD) detectors. The
functional imaging of SPECT and PET are fused with anatomical imag-
ing provided by X-ray Computed Tomography (CT).
• Ultra sound systems
A mice and rats US system (VisualSonics-VeVo2100 [98]). It is a high resolution
micro-ultrasound system with a 30 micron of spatial resolution), high frame
rates (up to 1000 fps), Color Doppler, 3D and contrast tools.
• Optical systems
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An in vivo imaging in the near-infrared (NIR) spectral region (Pearl Imager,
Licor [99]) for small animal imaging.
.
4.2 Employed sources
Within the PET/SPECT laboratory, both sealed and unsealed sources can be em-
ployed. The characteristics of the employed unsealed sources, with the maximum
overall activity that can be employed per year and the maximum total activity present
at a given time in the laboratory, are reported in Table 4.1. Table 4.2 reports the
features of the sealed source 137Cs employed for IsoMED 1010 calibrations.
Radio-
Decay mode
Half life Total Total Total Employ
nuclide (t1/2)
activity present activity
daysemployed activity per each
per year handling
(GBq) (GBq) (GBq)
18F β
+
1.83 h 11.1 0.25 0.06 86Eγ=511 keV
(68Ge) β+ 1.13 h 14.8 0.25 0.06 4068Ga Eγ=511 keV
177Lu multi γ-rays 6.71 d 7.4 0.25 0.2 9Eγ=113, 208 keV
99mTc γ-rays 6 h 1.86 0.25 0.2 48Eγ=140 keV
111In E.C. 2.7 d 0.74 0.25 0.2 14Eγ=172, 247 keV
Table 4.1: Characteristics of the employed unsealed sources.
Radionuclide Decay mode Half life Activity(t1/2) (MBq)
137Cs γ rays 30.2 y 3.7Eγ =661 keV
Table 4.2: Characteristics of the employed sealed source.
4.3. Rooms reserved for radioactives employing 51
4.3 Rooms reserved for radioactives employing
In order to reduce the radiation exposure to personnel, it was planned to reserve three
rooms for all the activities connected with the PET/SPECT imaging: the scan, the
console and the storage room (see figure 4.2).
Scan room
The layout of the scan room is reported in figure 4.4. Besides the PET/SPECT
scanner, YAP-(S)PET (see chapter 5), the following equipment are present:
• a radiation monitoring probe for X and γ area monitoring. The probe is a
ALMO-1 (SEA-GmbH) with a Geiger-Mu¨ller detector (GM, 18550 DE). Mea-
suring electronics and display unit are integrated in a plastic housing (see fig-
ure 4.6). On the front side of the housing, the large-area LCD display shows
the current measuring value of the connected detector. Two freely definable
alarm thresholds can be set. In case of exceeding an alarm threshold, an op-
tical/acoustic warning follows. We mounted the probe in the wall as far as
possible from possible radiation sources. The first alarm was set to 10 uSv/h.
• A chemical hood Valder Mc6 for radioactive handlings, used both for the prepa-
ration of calibration phantoms and radiotracers dose to be injected into the
animals. Inside the hood, we located a L-shaped shield with lead glass and sev-
eral lead bricks in order to reduce the body exposure to the personnel handling
radioactive stuff (see figure 3.2).
• A dose calibrator IsoMED 1010 (desktop version, GSG Robotix) (see figure
3.4) was placed close to the chemical hood and the YAP-(S)PET scanner. This
location allows to reduce the exposition time during the transportation of the
dose from the hood to the dose calibrator and from the dose calibrator to
the PET/SPECT scanner and to the YAP-(S)PET scanner back to the dose
calibrator for the residual assay.
• A gas anesthesia system composed by a gas pressure monitor for anesthetic
gas, a vaporizer, a filter for expiratory carbon dioxide (CO2) and isofluorane,
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and oxygen lines (see figure 4.7). The oxygen lines connect the vaporizer to
the supply tank that for safety reasons is located outside the CEIP, near the
rear entry (“Ingresso Sud 2” in figure 4.2). The gas anesthesia system provides
anestethic gas both to induction box (see figure 4.7) and PET/SPECT system
and allows a constant isofluorane influx to animals avoiding gas exposition to
personnel.
• A ventilated cabinet with stainless shelves (Tecniplast) (see figure 3.5) where to
store cages containing radioactive animals before returning them to vivarium.
The ventilation system creates a clean environment for housing rodents in cages
and minimizes the contamination level in the room air, thanks to the filtration
system which continuously re-circulates the air through the filtration an reduces
micro-organisms, dust and allergens and also reduces the risk of infections for
animals [100].
• A sink with holding tank for radioactive liquids (see figure 4.3).
• A radioactive waste container with pedal opening shielded with a 3 mm lead
thickness (Europrotex) (see figure 3.4) used to store all the potentially contam-
inated stuff (see section 3.5).
• A freezer for sacrified animals storage.
• A preparation table and a drawers.
The floor surfaces and the facing of the walls are realized with plastic material,
so that there is a minimum of dust collected and contamination can be removed.
The dimensions of the room are 4.5 m × 4 m and the separation wall between the
scan and the console room is provided with a lead-glass window that allow animal
status monitoring during experiments (see figure 4.3). The access to scan room is
restricted to authorized personnel wearing the personal dosimeter for both body and
extremities (finger dosimeter).
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Console room
The console room contains a PC for the management and analysis of PET/SPECT
acquisitions and a probe ALMO-1 (SEA-GmbH) with a Geiger-Mu¨ller detector (GM,
18550 DE), exactly alike the one installed in the scan room. The use of the PC is
restricted to personnel authorized to access to radioactive areas.
Storage room
This room, devoted to the storage of the liquid and solid radioactive wastes produced
during the activity, is equipped with (see figure 4.5):
• a ventilated cabinet with stainless shelves (Tecniplast) (see figure 3.5) where to
store cages containing radioactive animals injected with long-lived radiotracers
(see section 4.2) before returning them to vivarium.
• a refrigerator to storage the sacrificed animals carcasses.
• a radioactive waste (alike the one installed in the scan room) for storing all the
potentially contaminated stuff. As in the scan room, also in the storage room
the floor surfaces and the facing of the walls are realized with plastic material,
so that there is a minimum of dust collected and contamination can be removed.
Corridor
The corridor (see figure 4.2) is exclusively used as personnel passage among scan,
console and storage room. It is provided with a portable contamination monitor
(CoMo 170, see figure 4.6) equipped with a plastic scintillar ZnS (SEA-GmbH).
It is used to both detect for surface contaminations an to check for personal
contamination by radioactive material. The pulses measured (counts, activity or area-
based activity) can be made visible as a measured value and audible acoustic signals.
All measured data and information for operation are shown on a large LC display.
Essential system parameters and limit values can be set, among which automatic
background subtraction and defined alarm threshold (our alarm setting was fixed to
10 µSv/h). In addition, this portable contaminator monitor uses detector systems
on scintillator basis which in practical fields do not have the mechanical drawbacks
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of xenon detectors and do not have to be supplied with gas like gas-flow detectors.
With the scintillator detector α, β− and γ can be measured.
The access to the corridor is restricted to authorized personnel.
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Figure 4.3: Photo of sink with holding tank for radioactive liquids (left) and of the lead-
glass window present on the wall separating the scan and console rooms (right).
4.3.1 PET/SPECT laboratory shielding
As described in section 3.6, in order to determine the amount of necessary shielding
the transmission factor B has to be evaluated. It is then necessary to estimate the
PET/SPECT laboratory workload and to know the layout of the rooms in order to
calculate the dose produced at the desired distances beyond the shielding.
We have considered to perform from three up to five animal scans per day, on the
basis of the performed experiment (rats or mice). The injected activity per animal
spans in the range 7.4 - 44.4 MBq. The lower limit is referred to mice, the upper one
to rats.
The shielding calculation has been performed for both the scan and the storage
room.
Scan room
Due to number of imaged animals or to the radioisotopes used, the weekly workload
can differs greatly from one week to another. We have then evaluated the year
workload for each unsealed sources reported in Table 4.1. In particular, the following
values of the equation 3.6 factors have been considered:
• Dose rate constant, Γ: we have considered the Γ values related to the 10 ml
glass vial at a distance of 1 meter reported in [84] (see Table 4.12).
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Figure 4.4: Layout of the scan room reporting the distance used for transmission factor
evaluation.
• Activity, A: as a reference value we have considered the typical activity injected
per rat, 37 MBq.
• Number of animals imaged per week, Nw: we have considered four animals per
day, thus to obtain the year workload (instead of the weekly workload) we have
multiplied the number of animals per day per the employing days per year of
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Figure 4.5: Layout of the storage room reporting the distance used for transmission factor
evaluation.
Figure 4.6: Photo of ALMO-1 probe installed in the corridor (left) and of the CoMO
portable contamination monitor (right).
each radioisotopes (see Table 4.1).
• the number of hours the animal remains in the laboratory, th: to be conservative,
we have considered that the each animal remains in the scan room eight hours
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Figure 4.7: Photo of the gas vaporizer installed in the scan room for animal anesthesia.
a day.
• reduction factor, Rt: as time period, t, over which the total radiation dose is
received at a distance d from the emitting source, we have considered one day.
In the shielding calculation, we have considered only primary barriers.
Because of its twofold longer half-life compared to the other employed positron-
emitting radionuclides (68Ga) and to the higher dose rate constants respect to SPECT
radionuclides (see Table 4.12) we expect that shielding adequate for 18F should also
be adequate for all the employed radionuclides. Nevertheless, we have calculated the
transmission factor (B) for all the employed radioisotopes.
The shielding calculation has been performed by fixing the dose limit beyond
the shield (P) to 1 mSv/year for all the scan room’s adjacent areas. The occupancy
factors (T) of these areas are T = 1 for the control room and T = 1/4 for the corridor,
the external passage and the veterinary preparation room (see Figure 4.4). Since the
injected animals are the primary radiation source, it is necessary to identify the
locations within the scan room where the animals remain longer. The red circles of
Figure 4.4 highlight that these locations are the YAP-(S)PET scanner, the ventilated
cabinet and the preparation table. In particular, the locations closer to the scan room
walls are the ventilated cabinet and the preparation table. Thus, the calculation of
the transmission factor at the distances of these locations respect to the scan room
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walls will provide the amount of necessary shielding. Assuming the typical target
distances used for wall barrier, floor and ceiling calculation (see section 3.6), we have
calculated B at the following distance:
• at 0.6 meters (0.3 +0.3 meters) from the Wall 1.
• At 1 meters (0.7 +0.3 meters) from the Wall 2.
• At 0.6 meters (0.3 +0.3 meters) from the Wall 3.
• At 0.6 meters (0.3 +0.3 meters) from the Wall 4.
• At 2.1 meters ((2.8 +1) -1.7 meters) from the floor.
Since the scan room is located at the ground floor and has no rooms above, we
neglected to evaluate B for the ceiling.
As expected, the critical radioisotopes in determining the amount of shielding nec-
essary to assure that the effective dose in adjacent areas does not exceed 1 mSv/year
is 18F. Table 4.3 reports the evaluation of the transmission factors for all the walls
and the floor of the scan room.
Radio- Distance for Shielding
nuclide Wall barrier calculation B NTVL thickness
(m) (mm Pb)
18F 1 0.6 0.835 0.078 1.3
2 1 0.580 0.237 4
3 0.6 0.835 0.078 1.3
4 0.6 0.835 0.078 1.3
Floor 2.1 > 1 - -
Table 4.3: Evaluation of the transmission factors for 18F for all the walls and the floor of
the scan room.
The deduced lead thickness are 1.5 mm of lead for Wall 1, Wall 3 and Wall 4
and 4 mm of lead for Wall 2, while no shielding was necessary for the floor. On this
basis and aiming to limit the expenses, all the walls, except Wall 3, were shielded
with 1.5 mm thick lead sheets till 2 meters in height (being 1.7 meters the typical
human height). To reach the 4 mm necessary shielding on Wall 2, a 3 mm thick lead
sheet was applied on the back of the ventilated cabinet that is the main radiation
source from the scan room towards Wall 2. Since Wall 3 is one the border wall of the
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CEIP building, it provides at least 10 cm of concrete that are equivalent to 65 mm
of lead [90]. Thus, only a 1.5 thick lead sheet was applied on the windows of Wall 3
till 2 meters in height.
The total effective rate dose at 1 meter obtained by summing all the effective
doses of each isotopes is 11 mSv/year (see Table 4.12).
Storage room
The shielding calculation has been carried out following the same procedure used
for the scan room. To be conservative we have considered that inside the ventilated
cabinet can be present at the same time a number of animals three times as large as
the number of foreseen animals scanned per day per each isotopes. The occupancy
factors (T) of the areas surrounding the storage room are T = 1 for the surgery
room and T = 1/4 for all the other rooms (see Figure 4.5). As for scan room, the
transmission factor has been evaluated for all the employed radioisotopes. In the
storage room, the main radiation source is the ventilated cabinet and the distances
used for B calculation are the following:
• at 2.3 meters (2.0 +0.3 meters) from the Wall 1.
• At 1.1 meters (0.8 +0.3 meters) from the Wall 2.
• At 1.2 meters (0.9 +0.3 meters) from the Wall 3.
• At 1.3 meters (1.0 +0.3 meters) from the Wall 4.
• At 2.3 meters ((2.8 +1) -1.7 meters) from the ceiling.
• At 2.1 meters ((2.8 +1) -1.7 meters) from the floor.
Unlike the scan room, for the storage room 111In is the critical radioisotope in
determining the amount of shielding necessary to assure that the effective dose in
adjacent areas does not exceed 1 mSv/year (see Table 4.4).
This is due to the longer half life of 111In respect to 18F. 177Lu has a longer half
life respect to 111In but a smaller dose rate constant Γ and it is also foreseen to image
a smaller number of animals. The deduced lead thickness are 1.8 mm of lead for Wall
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Radio- Distance for Shielding
nuclide Wall barrier calculation B NTVL thickness
(m) (mm Pb)
111In 1 2.3 > 1 - -
2 1.1 0.252 0.599 1.8
3 1.2 0.300 0.523 1.6
4 1.3 0.352 0.453 1.4
Floor 2.3 > 1 - -
Ceiling 2.1 > 1 - -
Table 4.4: Evaluation of the transmission factors for 111In for all the walls and the floor of
the storage room.
2, 1.6 mm of lead for Wall 3 and 1.4 mm for Wall 4, while no shielding was necessary
neither for the floor nor for the ceiling. On this basis, it was decided to shield all
the walls, except Wall 3 with with a 2 mm thick lead sheets till 2 meters in height
(being 1.7 meters the typical human height). Wall 3 is one the border wall of the
CEIP building, it provides at least 10 cm of concrete that are equivalent to 65 mm
of lead [90]. Thus, only a 2 mm thick lead sheet was applied on the windows of Wall
3 till 2 meters in height. For safety reasons, also the Wall 1 was shielded with 2 mm
thick lead sheet. In fact, on this wall, separating the storage and the surgery room
are positioned a freezer for sacrified animals storage and radioactive waste container.
4.4 Evaluation of the dose to exposed personnel and
to the public
The evaluation of the dose to exposed personnel has been carried out on the basis
of the PET/SPECT laboratory workload as reported in section 4.3.1. In particular,
by taking in account the Total activity per each handling, the number of animals
scanned per day and the injected activity per animal.
As reported in section 3.2.1, doses due to both external and internal radiation
have to be evaluated.
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4.4.1 Dose evaluation to exposed personnel: external irradia-
tion
Three phases are related to external exposure:
• transportation
• preparation
• injection
For each phase both the effective dose and the equivalent dose to the lens of the
eye and to the hands have been evaluated for each employed sources reported in Table
4.1.
Transportation
A vial containing the radioactive compound is transported into the scan room inside
a lead pig enclosed in a transportation box (see figure 3.3) shielded with 3 centimeters
of lead. The trolley is introduced inside the CEIP building by the rear entry (“In-
gresso Sud 2” in figure 4.2) and then lead to the PET/SPECT laboratory following
the path highlighted in figure 4.2. The path is cleared in advance of not exposed
personnel, marked and delimited by appropriate stakes. Once inside the scan room,
the lead pig is removed from the transportation box and placed behind the L-shield
inside the chemical hood (see figure 3.2). The transportation phase is carried out
in a time span estimated by excess in 10 minutes. The trolley allows to maintain
a 50 centimeters distance between the exposed worker and the shielded radioactive
compound. The dose to exposed personnel has been evaluated for each employed
sources, by considering the Total activity employed per year (ATOT), the time of ex-
posure (texp) and the shielding due to the 3 centimeters of lead of the transportation
box. For the transportation phase, we assumed that the effective dose to the body
Ebody coincides with the equivalent dose to the lens of the eye and to the hands, Heye
and Hhands respectively, according to the following expression:
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Ebody ≡ Heye ≡ Hhands = Γ10mlvial@1m × ATOT × texp × 1
d2
× exp
(
−xPb · ln(10)
TVL
)
(4.1)
where xPb is the lead thickness of the transportation box shielding. The Γ con-
stant used in equation 4.1 refers to the irradiation produced by a 10 ml vial source
configuration at 1 meter of distance (see Table 4.5).
Radio- Half life Eγ Γ10 ml @ 1 m Ebody Ebody with 3 cm
nuclide (t1/2) (keV) (mSv m2 h-1 MBq-1) (mSv/y) Pb shielding
(mSv/y)
18F 1.83 h 511 1.58×10−4 1.17 0.020
68Ga 1.13 h 511 1.60×10−4 1.58 0.027
99mTc 6.71 d 210 6.36×10−5 0.31 0.001
177Lu 6 h 140 2.24×10−5 0.03 0
111In 2.7 d 245 7.17×10−5 0.04 0
TOTAL (mSv/y) 3.12 0.048
Table 4.5: External effective dose for the transportation phase.
Preparation
All the preparation issues are performed in the scan room, under the chemical hood,
standing behind the L-shield. The operator prepares the radiotracer dose to be
injected in the animal by wearing disposable gloves and by using spacer forceps to not
directly come in touch with the vials containing the radiotracers. Once prepared, the
dose is immediately placed inside the dose calibrator (see Figure 3.4) for radioactivity
assay. The dose preparation and the radioactivity assay are accomplished in an
estimated time span of 1 minute. Considering that can be carried out a maximum
of five animal studies per day, a total of 5 minutes per day has been considered for
the preparation phase. The dose to exposed personnel has been evaluated for each
employed sources, by considering the total activity per each handling (Ahands), the
total time of exposure (texp)per day, the distance between the exposed worker and
the radioactive compound (d) and the number of days each source is employed per
year (Ny). For the preparation phase, the effective dose to the body Ebody coincides
with the equivalent dose to the lens of the eye (Heye), while the equivalent dose to
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the hands (Hhands) has a different values. In fact, for Ebody and Heye a 50 centimeters
distance between the exposed personnel and the radioactive compound has been
considered, while for Hhands a 20 centimeters distance. Moreover, the 5 centimeters
of lead shielding of the L-shaped shield of lead have been considered in the Ebody and
Heye evaluation. For both effective dose and equivalent doses, the Γ constants used
refer to the irradiation produced by a point source configuration at 30 centimeters of
distance (see Table 4.6).
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Ebody and Heye have been evaluated according to the following expressions:
Ebody ≡ Heye = Γpoint source@30cm×Ahands× texp×
(
30
d
)2
×Ny× exp
(
−xPb · ln(10)
TV L
)
(4.2)
The expression related to Hhands is:
Hhands = Γpoint source@30cm × Ahands × texp ×
(
30
d
)2
× Ny (4.3)
Injection
The radiotracer administration is performed in the scan room with the animal anes-
thetized and positioned on the YAP-(S)PET bed. During this phase, the operator
directly handles the syringe containing the radioactive compound and injects it in
the animal. Immediately after, the syringe is inserted in the dose calibrator for the
residual activity assay. These two operations are carried out in an estimated time
span of 10 seconds. Considering that a maximum of five animal studies can be carried
out per day, a total of 50 seconds per day has been considered for the injection phase.
As for the preparation phase, the dose to exposed personnel has been evaluated for
each employed sources, by considering the Total activity per each handling (Ahands),
the total time of exposure (texp)per day, the distance between the exposed worker
and the radioactive compound (d) and the number of days each source is employed
per year (Ny), (see Table 4.7).
Radio- Half life Eγ Γpoint source @ 30 cm Ebody Heye Hhands
nuclide (t1/2) (keV) (mSv m2 h-1 MBq-1) (mSv/y) (mSv/y) (mSv/y)
18F 1.83 h 511 1.20×10−1 3.08 4.82 120.45
68Ga 1.13 h 511 1.03×10−1 1.23 1.92 48.09
99mTc 6.71 d 210 8.62×10−2 0.77 1.21 30.18
177Lu 6 h 140 2.61×10−4 0.01 0.02 0.49
111In 2.7 d 245 9.94×10−4 0.01 0.02 0.54
TOTAL (mSv/y) 5.11 8.00 199.75
Table 4.7: External effective dose Ebody, equivalent dose to the hands Hhands and to the
lens of the eye Eeye for the injection phase.
In the injection phase, each of the three dose quantities, (Ebody, Heye and Hhands)
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has a different values. The difference arises from the different considered distance
between the exposed worker and the radioactive compound. For Ebody a distance of
50 centimeters has been assumed, for Heye a 40 centimeters distance and 5 centimeters
for Hhands. As stated before, in the injection phase, neither for Ebody nor for the
equivalent doses Heye and Hhands a lead shield is present. For all the three dose
quantities, the Γ constants used refer to the irradiation produced by a point source
configuration at 30 centimeters of distance (see Table 4.7) and all the three dose
quantities have been evaluated according to the following expressions:
Ebody = Γpoint source@30cm × Ahands × texp ×
(
30
di
)2
× Ny (4.4)
where di indicates the different distance for Ebody, Heye and Hhands. Equation 4.4
applies also for Heye and Hhands evaluation.
Summary
Table 4.8 reports the total Ebody, Heye and Hhands estimated per a single exposed
personnel per year. The estimated doses are extremely precautionary, since the ra-
dioactive issues are nearly equally shared out among three operators.
Annual dose from external irradiation
Operation type (mSv/y)
Hhands Heye Ebody
Transportation - - 0.048
Preparation 192.53 0.029 0.029
Injection 199.75 8.00 5.11
TOTAL (mSv/y) 392.28 8.029 5.187
Population annual limit 50 15 1
Category A workers 500 150 20
Table 4.8: Total Ebody, Heye and Hhands estimated per a single exposed personnel per year.
4.4.2 Dose evaluation to exposed personnel: internal irradia-
tion
The possibility of internal irradiation is related to the event of air contamination and
following inhalation of radioactive steams or to the event of personal contamination
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and following ingestion of radioactive compounds. The evaluation of the effective
dose introduced by the exposed personnel has been carried out by multiplying the
estimated introduced activity per the dose coefficient per introduction unit reported
in the Table IV.1 of the enclosure IV of the D.Lgs. 230/95 and s.m.i. (see equation
3.3).
Inhalation
For each employed source, the inhaled dose per year has been carried out by multi-
plying the expected annual intake (Jina) by the dose coefficient per introduction unit
(hina) reported in the Table IV.1 of the enclosure IV of the D.Lgs. 230/95 and s.m.i.:
Eina = h(g)j,ina · Jj,ina (4.5)
where j indicates the j-th employed source.
The intake has been evaluated according to the following equation:
Jina = Cair · Vop · Nh,y · f (4.6)
where
• Cair is the specific average concentration of the air per hour and has been
evaluated according to equation 4.7.
• Vop is the air inhaled volume per hour by an exposed worker.
• Nh,y indicates the number of hours per year that the exposed personnel stays
in the scan room.
• f is the fraction of the contaminated compound inhaled.
Cair is calculated according to the following equation:
Cair =
AinstTOT
VPET
· rair (4.7)
where
• AinstTOT is the Total present activity (see Table 4.1).
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• VPET is the volume of the scan room.
• rair is the number of the change of the air per hour.
The values employed for the calculation of the inhaled dose per year are reported
in Table 4.9.
18F 68Ga 99mTc 177Lu 111In
AinstTOT (Bq) 0.25×109 0.25×109 0.25×109 0.25×109 0.25×109
VPET (m3) 49 49 49 49 49
rair 1 1 1 1 1
Cair (Bq/m3 h) 5.1×106 5.1×106 5.1×106 5.1×106 5.1×106
Vop (m3) 1.2 1.2 1.2 1.2 1.2
Nh,y (h) 220 220 220 220 220
f 1×10−6 1×10−6 1×10−6 1×10−6 1×10−6
Jina (Bq/year) 1.35×103 1.35×103 1.35×103 1.35×103 1.35×103
h(g)ina (Sv/Bq) 9.3×10−11 8.1×10−11 2.9×10−11 1.1×10−11 3.1×10−11
Inhaled dose per
year (mSv/y) 1.2×10−4 1.1×10−4 3.9×10−5 1.5×10−3 4.2×10−5
TOTAL inhaled dose
per year (mSv/y) 0.002
Table 4.9: Evaluation of the inhaled dose per year.
Ingestion
For each employed source, the ingested dose per year has been carried out by multi-
plying the expected annual intake (Jing) per the dose coefficient per introduction unit
(hina) reported in the Table IV.1 of the enclosure IV of the D.Lgs. 230/95 and s.m.i.:
Eing = h(g)j,ing · Jj,ing (4.8)
where j indicates the j-th employed source.
The intake has been evaluated as the product of the Total activity employed per
year (ATOT) and the fraction of radioactive compound ingested, according to the
following equation:
Jing = ATOT · f (4.9)
The values employed for the calculation of the ingested dose per year are reported
in Table 4.10.
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18F 68Ga 99mTc 177Lu 111In
ATOT (Bq/year) 11.1×109 14.8×109 1.85×109 7.4×109 0.74×109
f 1×10−5 1×10−5 1×10−5 1×10−5 1×10−5
Jing (Bq/year) 1.1×105 1.5×105 1.85×104 7.4×104 0.74×104
h(g)ing (Sv/Bq) 4.9×10−11 1.0×10−10 2.2×10−11 5.3×10−10 2.9×10−10
Ingested dose per
year (mSv/y) 5.4×10−3 1.5×10−2 0.4×10−4 3.9×10−2 2.1×10−3
TOTAL ingested dose
per year (mSv/y) 0.061
Table 4.10: Evaluation of the ingested dose per year.
4.4.3 Dose evaluation for CEIP workers not assigned to PET/SPECT
laboratory
The regulatory issues of the PET/SPECT laboratory (see section 4.6), the delimita-
tion and signaling during the transportation process do not lead to suppose significant
situations of not justified exposition to not the workers not assigned to PET/SPECT
laboratory. In fact, the dose to workers not assigned to PET/SPECT laboratory is
assumed to be negligible.
4.4.4 Dose evaluation for the public
The regulatory issues of the PET/SPECT laboratory (see section 4.6) and of the
CEIP do not lead to assume significant situations of not justified exposition to the
public. The dose for the public is evaluated as zero.
4.4.5 Evaluation in case of accident
For each employed source, we have considered the contribution in the case of an
accidental contamination as the ingestion of a vial containing all the activity that
can be injected in a rat in a single study. The accidentally ingested dose is obtained
by multiplying the activity contained in the vial (Avial) by the dose coefficient per
ingestion (hing). The data are reported in Table 4.11.
Nevertheless, due to the low probability that an accidental ingestion can be occur,
this contribution can be neglected.
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18F 68Ga 99mTc 177Lu 111In
Avial (Bq) 44.4×106 44.4×106 44.4×106 44.4×106 44.4×106
h(g)ing (Sv/Bq) 4.9×10−11 1.0×10−10 2.2×10−11 5.3×10−10 2.9×10−10
Accidentally Ingested dose
per year (mSv/y) 2.2×10−3 4.4×10−3 1×10−3 23.6×10−3 12.9×10−3
TOTAL accidental
contamination dose 44.1
per year (mSv/y)
Table 4.11: Evaluation of the accidental contamination dose per year.
4.5 Production and management of radioactive wastes
Concerning the production and management of radioactive wastes, two processes have
to be taken in account: the management of the solid wastes and the disposal of the
injected animals.
Management of solid wastes
The solid wastes main sources are disposable gloves, blotting paper used for surface
protection, syringes and other small stuff used during radiotracer administration,
decontamination stuff, empty vials containing small amounts of radiotracer no more
employed.
The wastes are kept in the shielded container inside the scan or the storage room
(see section 4.3) for a time span of at least 5 half lives of the relative employed source
and anyway till the radioactive concentration will be lower than 1 Bq/g, as stated by
the D.Lgs. 230/95 and s.m.i.
Storage of the radioactive animals
Two possible cases have to be managed:
1) If the animals are injected with the short half life radioisotopes, like 18F and
68Ga, are not sacrificed, the day after the PET scan can be returned to the
vivarium.
2) The animals injected with radioisotopes with longer half lives (177Lu and 111In)
and not sacrificed, will be stored in the ventilated cabinet placed inside the
storage room for a time span of at least 5 half lives of the employed source and
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anyway till the radioactive concentration will be lower than 1 Bq/g, as stated
by the D.Lgs. 230/95 and s.m.i.
4.6 Classification of the areas and of the workers
Areas classification
As reported in section 4.3.1, the scan room total effective rate dose at 1 meter obtained
by summing all the effective doses of each isotopes is 11 mSv/year (see Table 4.12).
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On the basis and considering that the employed sources are unsealed, the whole
the PET/SPECT laboratory has been classified as controlled room.
Appropriate marks pointing out that the area is controlled and the symbol indicat-
ing the radioactive risk must be displayed on the entrance doors of the PET/SPECT
laboratory (see Figure 4.8) together with the list of people authorized to enter the
the laboratory.
Figure 4.8: Photo of the controlled area mark.
Workers classification
The workers classification is carried out on the basis on the effective and equivalent
doses evaluation due to the workloads, on the periodic dosimetric controls performed
on the exposed personnel and on the possible risks related to the use of the employed
sources. The evaluation of the total effective dose (Ebody) and of the equivalent dose
to the eye (Heye) (around 5 and 8 mSv/y, respectively, see Table 4.8) could lead to
classified the workers in category B, but the high equivalent dose to the hand (Hhands
close to the limit for the A exposed workers) led us to classify the PET/SPECT labo-
ratory workers in category A. The exposed personnel will be subjected to dosimetric
control by both body and extremities dosimeters. The extremities dosimeters should
be also sensible to β radiation. For a better evaluation of the dose absorbed by the ex-
posed personnel, a few environmental dosimeters will be employed. These dosimeters
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will be placed close to the preparation sites (on the lead glass of the L-shaped shield,
see Figure 3.2), to the injection sites (in particular below the YAP-(S)PET bed, close
to the operator body) and on the walls that separate the control and the storage
room from the scan room. Furthermore, the exposed personnel will be subjected to
medical supervision that foresees medical checks performed every six months by an
Authorized Doctor.
All the remaining CEIP people will be considered as Public.
Chapter 5
The YAP-(S)PET scanner
The YAP-(S)PET is a small animal scanner specifically built to perform PET and
SPECT acquisitions. For this reason the scanner uses planar detectors rather than
the more common cylindrical multiring configuration. Another peculiarity is the
utilization of YAlO3:Ce (or YAP:Ce) as scintillator crystal.
The scanner was originally developed (( [101,102]) ) at the Department of Physics
of the Universities of Ferrara and Pisa, Italy.
From 2003, fully engineered versions of the scanner have been produced and com-
mercialized by the small italian company I.S.E. Ingegneria dei Sistemi Elettronici
s.r.l., Pisa, Italy [103]. One of these scanners has been purchased by the Molecular
Biotechnology Center of the University of Torino installed within the CEIP 4.1, inside
the Bioinsustry Park site in Colleretto Giacosa.
The the scanner had a detector array composed of a 4 × 4 cm2 matrix of YAP:Ce
of 20 × 20 crystals, each crystal being 2 × 2 mm wide and 25 mm long.
5.1 The YAP-(S)PET scanner overview
The scanner is made of four detector heads of pixellated crystals of YAP:Ce. Each
matrix consist of 400 (20 × 20) elements of 2 × 2 × 25 mm3 glued together, and
optically isolated by a 5 µm thick reflective layer. This very thin and efficient reflective
layer is applied by the manufacturer (Crytur [104]). The matrix is directly coupled to
a position sensitive photomultiplier tube (PS-PMT Hamamatsu R2486, Hamamatsu
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Photonics, Hamamatsu City, Japan).
The distance between detectors pairs is fixed to 15 cm in the commercial version.
The four modules are positioned on a rotating gantry (see figure 5.1) and opposing
detectors are in time coincidence when used in PET mode.
The scanner can be switched between PET and SPECT modalities without any
change in the detector configuration or in the acquisition system, but simply replacing
the tungsten septum (used in PET for shielding the scintillator from the background
outside the field-of-view (FOV)) with a high-resolution parallel hole collimator in
front of each crystal.
The YAP-(S)PET computing architecture is client/server: the on-site PC (server)
that performs data acquisition and motion control can be controlled by a remote PC
(client) connected to a local network.
The PC-controlled head rotation allows tomographic acquisition. The scanner
is equipped with a laser system and motorized bed for the animal positioning and
motion within FOV. The axial motion of the bed can be controlled via a PC software,
while the vertical position of the bed can be adjusted manually. There are two bed
models available, and both of them have a carbon composition. The flat one (4 cm
wide and 50 cm long) is specifically designed for mice holding, while the hollow bed
(50 mm in diameter and 50 cm in length) is more suitable for rats (see figure 5.2).
For both PET and SPECT modalities the scanner has an axial and transaxial
FOV of 4 cm.
5.2 The main hardware components
5.2.1 Scintillator crystals: YAP:Ce
The ideal detector material for PET systems stops all photons that enter the detec-
tor, and provides high spatial, temporal and energy resolution for the recorded event.
These parameters could not be optimized simultaneously in one single detector ma-
terial or geometry; the optimal PET device must be matched to the source geometry
and imaging requirements [105].
In recent years, there has been considerable research in new PET scintillator
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Figure 5.1: Photograph of the YAP-(S)PET scanner.
Figure 5.2: Photograph of the two bed models available with the YAP-(S)PET scanner:
the flat one (bottom of the figure) for specifically designed for mice holding, and the hollow
bed (top) more suitable for rats.
materials, especially for high Z materials, to improve the performance of future PET
scanners. An important example is LuAP:Ce, with its high Z, high-density, fast decay
time and relatively high light yield [106]. In high Z materials, the one gamma mean
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free path has a shorter extension respect to low Z materials. 90% absorption lengths
for 511 KeV photons is about 25 mm in BGO and more than the double in YAP [107].
Moreover, multiple interactions of the incident photon in the detector (such as when
the photon undergoes a Compton interaction or a photoelectric interaction with an
inner shell electron, with subsequent X-ray emission) are generally closely spaced.
All these effects can limit the achievable spatial resolution. In the past [108], low Z
plastic detectors have been considered for positron imaging due to the relative low
cost. Subsequently, interest has been related to its speed and potential high spatial
resolution [105].
Low Z materials have a photoelectric to Compton ratio very low compared to high
Z detectors. However, the photon which emerges from the first Compton interaction
would travel a large distance from the interaction site. Besides, multiple interactions,
especially in thin detectors, will be high improbable. Energy resolution to distin-
guish true and scattered photons will not be possible, since there is no photopeak.
However, locating the site of a photon interaction by using the light produced by a
single Compton electron provides low Z detectors the potential for very high spatial
resolution. A similar behaviour is expected using a medium-Z scintillator, such as
YAP.
Yttrium Aluminum Perovskite activated by Cerium (YAlO3:Ce or YAP:Ce) is a
monocrystal with the structure of perovskite. The crystal is very hard, mechanically
and chemically stable, and it is not hygroscopic. Its main features are fast scintillation
emission and high light yield that makes this crystal the best compromise for both
PET and SPECT applications [102]. Besides, it can be assembled in crystal matrices
with small pixels for high spatial resolution maintaining its high light output. Other
scintillators, typically used in PET, either do not generate enough light (BGO) for
being used at the energy (140 keV) of the main used SPECT radiotracer (99mTc), are
too expensive (GSO) or are intrinsically radioactive producing signals in the relevant
energy range (LSO: about 400 cps/cm3). In table 5.1, the main characteristics of
YAP:Ce are summarized and compared with those of other scintillators [109].
Due to the low photoelectric/Compton ratio in YAP:Ce (4.4 % at 511 keV), most
of the events which contribute to the total absorption peak derive from multiple
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Material NaI:Tl CsI:Tl BGO GSO:Ce YAP:Ce LSO:Ce
Z 11/53 55/53 83/32/8 64/14/8 39/13/8 71/14/8
Effective
atomic number 51 54 74 60 33 67
(511 keV)
Density (g/cm3) 3.67 4.53 7.13 6.71 5.37 7.42
Index of refraction 1.85 1.80 2.20 1.90 1.95 1.82
Hygroscopic? yes slightly no no no no
Natural
radioactivity no no no no no yes
Wavelength
of maximum 415 550 480 440 370 420
emission (nm)
Decay 30-60 (90%)/ 12/
constant (ns) 230 900 300 600 25 40 (65%)
Radiation length
(cm) 2.9 1.86 1.1 1.38 2.7 1.14
Gamma
Mean Free Path 3.05 2.43 1.11 1.43 2.18 1.22
(511 keV) (cm)
Photoelectric
fraction 18% 22% 44% 25% 4.4% 32%
(511 keV)
Photoelectric
fraction 84% 87% 94% 82.3% 46% 92%
(140 keV)
Absolute light
yield 300 K 38 52 8-9 9-10 17 27-30
(103 photons/MeV)
Table 5.1: Basic characteristics of some scintillator crystals.
interactions within the crystal and not from photoelectric absorption. The position
of one event is the average value of the coordinates of each interaction weighted by
its energy deposition. Hence, the spatial resolution for multiple interactions events
deteriorates. Selecting a suitable energy window mostly single Compton events are
registered and a higher spatial resolution can be obtained.
Figure 5.3 shows simulated pulse height distributions obtained for different num-
bers of photon interactions within the YAP:Ce matrix.
It is evident that most of single interaction events have a pulse height below
400 keV, i.e., the valley in the pulse height distribution of Fig. 5.3. In small animal
scanners, the scattering from rats or mice is not so important as in clinical scanner, so
the single Compton events can be considered “good events”. For this reason, YAP:Ce
shows better spatial resolution capabilities with respect to high Z scintillators, such as
BGO [110]. Since all high Z scintillators have a photofraction below 50% at 511 keV
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Figure 5.3: Simulated pulse height distributions obtained for different numbers of photon
interactions within the YAP:Ce matrix.
the events under the full energy peak will have a large contribution from multiple
Compton scattering in the crystal. These events are usually chosen as the “best”
events. In dense medium Z scintillators, like YAP, by selecting only Compton events,
even in a crystal whose thickness is one gamma mean free path, a high fraction of
these (≈ 60%) will be single interactions, providing, therefore, the correct interaction
position. This percentage is more than any photofraction of any scintillator.
In the YAP-(S)PET scanner it is possible to select the energy window in which
data for reconstruction are taken. In PET mode, choosing the 50-400 keV window
the single Compton events are favoured and a higher spatial resolution reconstruction
is obtained. On the other hand, selecting the whole spectrum (50-850 keV) a higher
sensitivity is obtained.
Chapter 4 of [111] reports the spatial resolution and the sensitivity for both 50-400
and 50-850 keV energy window. The results clearly show how the spatial resolution
improves when using the high spatial resolution energy window (50-400 keV), while
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there is a significant decrease in sensitivity.
The use of the reduced energy window (140-250 keV) in SPECT mode is justified
by a reduction in scatter contribution, as described in [112]. In this article, it is
shown how above 140 keV there are about no scatter tails. The test acquisition
was performed with a 10 mm diameter cylindrical phantom, filled with 99mTc and
surrounded by a 11 mm thick lucite ring.
Thus, in SPECT mode, in this thesis we have always used the reduced energy
window 140-250 keV.
5.2.2 Position Sensitive Photomultiplier Tube (PSPMT)
Before the advent of the Position Sensitive Photomultiplier Tube (PSPMT), the task
of obtaining 2-dimensional information required the use of an arrangement of multiple
PMTs. This approach was quite expensive and required complex hardware. The
R2486 series was the first 3 inch position sensitive PMT developed by Hamamatsu
in 1985 [113], and represented a strong technological advancement for gamma ray
imaging.
Figure 5.4: Photograph of the R2486 PS-PMT tube by Hamamatsu [114].
The R2486 tube (see figure 5.4) consists of a 3 inch PMT with bi-alkali photo-
cathode, 12-stage coarse mesh dynode structure, and 16×16 anode wires crossing one
another in the X and Y directions. The dynode structure consists of two layers: a
focusing grid and multiplication bars. The bars are alternatively crossed to obtain
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Figure 5.5: Dimensional outline (on the left) and anode pattern (on the right) of the R2486
PSPMT tube by Hamamatsu [114].
multiplication along the X and the Y direction (see figure 5.6). A charge cloud is gen-
erated across the 12 dynode stages and finally collected by a crossed wire anode (see
figure 5.5). The focusing structure limits the spread of the charge (obtained from a
point-like illumination of the photocatode) to 4.3 mm at the last dynode [113], where
the charge is back-reflected to the anode wires. The wire pitch is 3.75 mm, thus giving
adequate sampling of the charge distribution. The intrinsic spatial resolution of the
R2486 tubes ranges between 0.9 mm and 0.12 mm, which improves with increasing
charge on the anode. The tube has a circular photo-cathode with an active area of
50 mm in diameter, with respect to an overall diameter of 76 mm. Figure 5.5 shows
the dimensional outline and the arrangement of the anode wires. In the standard
configuration, the two wire ends of wires in the same direction are connected via a
resistive chain. The two ends of each resistive chain (X or Y) produce two charge
pulses: Xa and Xb (or Ya and Yb) . The final position is then given by the equation:
X =
Xa − Xb
Xa + Xb
(5.1)
The general characteristics of the PSPMT R2486 are reported in table 5.2.
5.2.3 Electronic read-out
The electronic equipment is mounted on the back of the rotating gantry of the YAP-
(S)PET scanner (see figure 5.7). It consists of:
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Figure 5.6: Coarse mesh dynode structure. Left: schematic representation of a cross-
section of a PSPMT obtained linking digitized images from electronic microscope of dynode
cross-section. The figure represents the multiplication process along the X direction where
G is the hexagonal grid, D is the bar dynode and K is the bi-alkali photocathode. Right:
front view image of the coarse mesh dynode obtained by an optical microscope [115].
• four High Voltage (HV) units that supply the power to each of the R2486
PSPMTs. The HV value can be set independently for each PSPMT (see figure
5.8). This feature allows to better exploit the Analog to Digital Converter
(ADC) dynamic range [116].
• two acquisition boards with dedicated and compact electronic devices for the
PSPMTs signal amplification and digitization. Each acquisition board is dedi-
cated to a pair of opposite detectors both in PET and SPECT modalities.
Each PSPMT has two different type of output signals: the last dynode and the
four anodic position signals.
The last dynode signals are used for fast timing coincidence. The output signal
from each PSPMT is amplified by a pre-amplification stage produced by ISEsrl
and then sent to the acquisition board for fast timing coincidence. A Constant
Fraction Discriminator (CFD) is used for each photomultiplier tube. In PET
mode, the logic outputs of the CFDs of opposing detectors are sent to a coinci-
dence module that produces the gate signal for the acquisition of the position
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R2486
Spectral response 300 nm to 600 nm
Wavelength of maximum response 420 nm
Photocatode material Bialkali
Minimum effective area 50 mm diameter
Window material (thickness) Borosilicate glass (3.0 ± 0.3 mm)
Dynode structure Coarse mesh
Number of dynode stages 12
Anode structure 16 (X) + 16 (Y) crossed wires
Max HV -1300 V
Max gain 5.0 × 105
Signal rise time 5.5 ns
Table 5.2: General characteristics of the Hamamatsu R2486 photomultiplier tube
[114].
signals (see figure 5.9). One of the CFD outputs of each pair of detectors is
delayed by 100 ns in order to generate a delayed coincidence window. Events
collected in this window are random events and are used to establish the rate of
the randoms used for random corrections [116]. In SPECT mode, the output of
each CFD directly generates the gate for the acquisition of the position signals.
The X-Y signals from the PSPMTs are used to determine the energy deposited
by the γ-rays and the position of detected events. The four position signals
from each PSPMT are processed by a system composed of a peak detector and
a peak sensing ADC. The digitization of the signals is enabled by the gate
signal.
The digital data are transferred to the local PC sever via USB2 connection. Electronic
issues are controlled by two board called FAB (Fast Acquisition Board) (see figure
5.10)
5.2.4 SPECT collimator
The purpose of a collimator is to form the projection image by permitting gamma-
rays photons approaching the camera from certain directions to reach the crystals
while absorbing most of the other photons. Several kinds of collimator can be found:
pinhole, parallel-hole, converging and diverging holes, fan beam and more. The most
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Figure 5.7: Photogtaph of the YAP-(S)PET electronics on the back of the gantry.
Figure 5.8: The four high-voltage (HV) supplies for each PSPMT of the YAP-(S)PET
scanner.
commonly used collimator is the parallel-hole, particularly for human scanners. In
small animal imaging, where one would like a spatial resolution between 1 and 3 mm,
one of the difficulties of this design is to make very small diameter but long collimator
holes [117].
In the YAP-(S)PET scanner the collimators can be easily mounted or removed
from the detectors head, replacing the tungsten septum used in PET for shielding the
scintillators from the background outside the FOV (see figure 5.11). The collimators
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Figure 5.9: Schematic representation of the electronics for the coincidence acquisition of
the signals from a pair of opposing detectors.
Figure 5.10: The acquisition board FAB (Fast Acquisition Board) of the YAP-(S)PET
scanner.
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are made of lead with 0.6 mm hexagonal holes and are 20 mm thick. The septa
between holes are 0.15 mm. A particular of the holes of the collimator is shown in
figure 5.11. The collimator geometrical efficiency g, defined as the fraction of gamma-
rays passing through the collimator per gamma-rays emitted by the source toward
the collimator, is given by [118] g ≈ [K d2/L(d + t)]2, where d is the hole diameter,
L is the thickness of the collimator, t is the thickness of the intra hole septa and K
is a factor depending on the geometry of the holes. In the case of hexagonal holes
K=0.26. With d=0.6 mm, t=0.15 mm, and L=20 mm the geometrical efficiency
results 4×10−5.
Figure 5.11: PET septum and SPECT collimator (on the left) with zoom of the collimator
holes (on the right).
5.3 The software tools
5.3.1 Client/server architecture
The YAP-(S)PET scanner architecture is client/server.
The on-site PC (server) is dedicated to electronic equipment control, data acqui-
sition and motion control.
In the next sections, I will go through a detailed description of the YAP-(S)PET
client characteristics. It will help the comprehension of the next chapters.
The YAP-(S)PET client application is characterized by a user-friendly graphic
interface. It allows to check and set up all the parameters regarding data acquisition,
data analysis and image reconstruction from any remote computer connected via a
local network to the server.
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The YAP-(S)PET client main panel houses some menus and a command window
with four icons (see figure 5.12).
The menus are: File and Operations. The Operations menu contains two groups
of commands. The “Operative phase” group includes the same commands of the
icons of the command window. The “Server-side operations” menu allows to choose
the scanner acquisition mode (PET or SPECT), and to set the distance between the
heads of each couple.
Each icon of the command window corresponds to a different command: Acqui-
sition, Analysis, Reconstruction and Display.
Figure 5.12: Main panel of the YAP-(S)PET client graphic user-friendly interface.
5.3.2 Acquisition
The Acquisition panel (see figure 5.13) allows to set the acquisition parameters. Two
different types of acquisitions are possible: Preset Count and Preset Time.
In Preset Count mode, the counting interval ends when a preselected number of
events has been acquired.
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In Preset Time mode, the counting interval begins when the Start button is
pressed and is terminated automatically when the selected counting time has elapsed.
Different parameters can be set for both the acquisition modalities:
• the number of views, ranging from 1 (planar acquisition) to 128. The step is
2n, with n running between 0 and 7.
• in Preset Count mode only, the number of events per view. Actually, the user
can set the number of blocks to be acquired per view. Each block contains 63
events, all of them are registered with the same time label with respect to the
beginning of the acquisition. The number of blocks ranges from 1 to 108.
• in Preset Time mode only, the number of acquisitions, the duration (in time)
and the delay between an acquisition and the following one. This acquisition
mode is particularly suitable for dynamic acquisitions.
• the start and the end angle of gantry rotation. The start angle ranges from 00
to 3590. The end angle can be 900, 1800 or 3600. If the number of views is equal
to 1, the start and end angles coincide.
• the bed initial position and the total length to scan. The whole-body acquisi-
tions are performed with the standard protocol of translating the bed through
the scanner at discrete, overlapping steps. Each step requires a bed advance-
ment of 20 mm, i.e., half of the FOV dimension. The maximum length to scan
is 160 mm, corresponding to 7 bed positions.
• the radioisotope used for the acquisition. This information is used by the Client
software to correct acquired data for decay process.
• injection time of the radioisotope. It is an important parameter for tracer
kinetic modeling.
Some parameters displayed in the Acquisition panel allow to monitor the progress
of the acquisition:
• the total number of the acquired events.
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• the remaining time, that is the time remaining to the end of the acquisition.
In Preset Count mode, the computation of the remaining time is performed on
the basis of the rate of acquired events and the decay time of the radioisotope
used.
• several on-line counters that measure the rate of acquired events by each single
head or pair of heads. The displayed rate (cps) are: registered events by each
pair of heads; single events acquired by each head; true coincidence registered by
each couple of heads; false coincidence acquired by each couple of heads; pile-up
events acquired by each head; saturation events registered by each head.
• the number of the current view in the running acquisition and the corresponding
gantry angle (in degrees).
• the number of the acquired events in the current view.
• the number of bed positions for whole body studies and the number of acquisi-
tion in dynamic studies.
5.3.3 Analysis
Analysis, as Reconstruction and Display tools, can be accessed by clicking on the
corresponding icon in the Acquisition panel (figure 5.12). The selection of the file
opens the Yappet File Manager window (see figure 5.14).
The Analysis tool concerns the raw data analysis and the sinograms production.
The data are acquired in list-mode binary format and stored in memory in blocks
of 64 events. For each pair of γ-rays detected in PET mode, the four position signals
from each PSPMT and the related time are registered. In SPECT mode, the detection
of a single γ-ray implies the registration of the four position signals of the single
PSPMT and the related time.
Two different type of list-mode files can be produced and processed: the calibra-
tion and measurement files.
The calibration acquisitions are used in the calibration and maintenance phases
of the scanner. The raw analysis that is possible to perform on these files generates:
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Figure 5.13: Acquisition panel of the YAP-(S)PET client user interface during a calibration
measurement in PET mode.
• the planar image of each YAP:Ce matrix, used for the pixel identification and
the generation of a Look Up Table (LUT) of the geometric position of each
single crystal.
• the energy spectrum of each single crystal and the sum of them for each head,
necessary to perform the energy calibration and to check the proper function-
ality of the scanner.
• the efficiency corrections used to normalize the yield of the different crystals of
each matrix [116].
It is possible to choose the raw ADC channel limits for each analysis performed.
Measurement acquisitions refer to all the non calibration acquisitions gen-
erally performed. The measurement list-mode files can be processed as calibration
acquisition besides allowing the sinogram generation.
The system operates in 3-D data acquisition mode without septa. The collected
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Figure 5.14: Yappet File Manager window for Analysis, Reconstruction and Display opened
from a static acquisition of a the derenzo-like phantom list-mode file.
data can be stored in 2-D (PET and SPECT mode) or 3-D (only PET mode) sino-
grams.
In 2-D sinograms only data coming from direct planes are processed and the
oblique lines of response (LORs) are rejected.
The 3-D sinograms (3-D Positron Volume Imaging o 3-D PVI) take in account
both direct and cross-plane detected events, thus storing all the coincidence data
acquired by the scanner. Two different approaches are usually used to reconstruct
from 3-D coincidence PET data: the rebinning algorithms and the fully 3-D approach
of the 3-D reprojection (3-DRP) [119].
The 3-DRP algorithm is a 3D extension of the 2D filtered backprojection (FBP)
algorithm and has a very high computational complexity.
This is why at present the YAP-(S)PET Analysis tool implements only rebinning
algorithms: single slice rebinning (SSRB or MSRB) and Fourier rebinning (FORE).
A rebinning algorithm is defined as an algorithm which sorts (rebins) the 3-D
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acquired data into a stack of ordinary 2-D sinograms. These rebinned data are
geometrically equivalent to data collected in the conventional 2-D mode and can
therefore be reconstructed by applying 2-D reconstruction algorithms (FBP, OSEM)
to each slice separately. Unlike standard 2-D sinograms, the rebinned sinograms
are less noisy because they employ much more data (the oblique LORs) than those
acquired in 2-D mode [120].
In the SSRB or MSRB algorithm, each oblique coincidence line is assumed to have
arisen from a parallel plane midway between the axial points of interaction of the two
γ-rays in the opposite detectors [121]. Along the central axis of the scanner, this
approximation works perfectly. However, it steadily becomes worse with increasing
distance from the central axis. This approach yields reasonably acceptable images
when the object being imaged takes up a small fraction of the FOV and when the
axial acceptance angle (the maximum oblique angle accepted) is small [122]. In the
YAP-(S)PET Analysis tool, the SSRB maximum span is fixed to 15 LORs, while
MSRB accept all the possible inclinations of the LORs.
The FORE technique relates the 2-D Fourier transform of an oblique sinogram
to the 2-D Fourier transform of the direct sinogram of a slice shifted axially by a
frequency-dependent offset. Although this is still an approximate method, it yields
substantially better results than SSRB, even for large objects and large acceptance
angles [123], while retaining much of the advantage in terms of short reconstruction
times.
In SPECT mode, each sinogram for each head can be produced besides the sino-
gram sum. Each sinogram is composed of 27 slices (1.5 mm thickness), has 53 spatial
bins (the number of bins used to digitize the radial positions respect to the center
of the FOV) and a number of angular bins depending on the number of views of
the SPECT acquisition and on the angular rebinning. For example, in a SPECT
acquisition of 128 views over 1800, the number of angular bins will be 128 with
angular rebinning or 256 without rebinning (sinogram produced over 1800 or 3600
respectively).
In PET mode, the single sinogram is related to the couple of detectors instead
of the single head. The sinograms can be produced with both 27 or 53 slices (1.5 or
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0.75 mm thickness) in order optimize the axial sampling of the 3D image. The single
slice has 53 spatial bins and a number of angular bins depending on the head-to-head
distance (see section 5.1) and on the angular rebinning. The angular rebinning is
determined on the basis of the minimum detectable angle (δmin). Referring to figure
5.15, the mathematical expression of δmin is:
tan(δmin) =
lsino
2(R + DOI)
≈ δmin (5.2)
lsino is the spatial sampling, R is half the head-to-head distance and DOI is the
most probable interaction depth (in the YAP-(S)PET “27 × 27” version it is set to 8
mm).
The approximation is justified up to lsino  R. In our case, lsino is 1.5 mm or 0.75
mm and R ranges from 50 to 75 mm. The number of angular bins (Nθ) over 3600 is
obtained by the expression:
Nθ =
pi
δmin
(5.3)
If a PET acquisition is performed, i.e., in the configuration with head-to-head
distance of 12.5 cm (R=62.5 mm), Nθ will be 148 or 296 according to the sinogram
produced with or without angular rebinning.
Figure 5.15: Left: Two detectors of a detection couple (PET modality) faced one another.
The minimum detectable angle is visualized . Right: Sketch of the geometric configuration
for the determination of the number of angular bins.
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During each analysis process of both calibration or measurement acquisitions, a log
file containing information about the acquisition is created. The log file is structured
as a table, whose rows refer to a single view of the acquisition (see figure 5.16). The
final row reports the whole contribution of all the views. For each performed scan
(dynamic frame or bed position) a table is generated. The columns of each table
contain the following information (from left to right of figure 5.16):
• percentage of acquired events effectively used in the analysis.
• percentage of rejected events for energy values.
• percentage of rejected events for ADC values.
• percentage of real events. This percentage is obtained by the number of CFD
triggers. The CFD starts every time a good event arrives. Nevertheless, due
to dead time, during the acquisition of one event the electronic equipment can
be unable to detect another event. By registering the number of CFD triggers,
it is then possible to know the number of real events and to express them as
a percentage of the acquired events (obviously this percentage is greater than
100%).
• percentage of random events, available only in PET modality. (See section 5.2.3
for the explanation on the determination of random events).
• percentages of events used by each head (FT in figure 5.16 stands for pho-
totube). These percentages are related to the percentage of acquired events
effectively used in the analysis (column Used of figure 5.16).
• duration of the acquisition of the view.
5.3.4 Reconstruction
The goal of image reconstruction is to obtain the 3D distribution of the activity in
the object that is being scanned, using externally detected radiation. In order to
perform tomographic reconstruction, a set of “views” should be acquired at discrete
angles around the object, so that each view supplies a 2-D projection of the 3-D
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Figure 5.16: Log file of a static acquisition of a derenzo-like phantom.
activity distribution. As explained before, in the YAP-(S)PET scanner this set of
2-D projections is sorted in a set of 2-D sinograms. The 3-D image is then composed
by stacking the slices reconstructed with 2-D methods.
In the YAP-(S)PET software, once the acquired data are stored in sinograms (see
section 5.3.2), different type of reconstruction can be performed. The Filtered Back
Projection (FBP), the Maximum Likelihood Expectation Maximization
(ML−EM) and the Ordered Subsets Expectation Maximization (OSEM).
The FBP is an analytic reconstruction algorithm that uses the central-section
theorem. The implementation is based on the following steps [122]:
• compute the 1-D Fourier transform of the first projection angle in the sinogram;
• multiply this by the filter function;
• take the inverse Fourier transform;
• backproject the modified (filtered) projection;
• repeat the procedure for all angles around the object.
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Figure 5.17: Image Reconstruction panel with FBP reconstruction selected. The cut-off
frequency expressed in pixel actually is expressed in pixel/FOV.
The mathematical formulation is:
f(x, y) =
1
N
N∑
i=1
p′(x cosφi + y sinφi, φi) (5.4)
where
p′(r, φ) = 1
2pi
FT−1{FT[p(r , φi)] · |νr |} (5.5)
FT and FT−1 are the direct and inverse Fourier transform, respectively. N is
the number of different equally spaced projection angles over which data have been
acquired: p(r, φi) is the number of counts in the sinogram element angle φi and radial
offset r, and f(x,y) is the activity distribution. |ν| is the reconstruction filter, known as
Ram-Lak (Ramachandran and Lakshminarayanan [124]) or ramp filter because of its
shape in frequency domain (see figure 5.18). It amplifies the high-spatial frequencies
with respect to the low-spatial frequencies. The typical 1/r blurring effect introduced
by the backprojection is so reversed.
100 Chapter 5. The YAP-(S)PET scanner
Amplification of the high-spatial frequencies also leads to amplification of high-
frequency noise. A typical projection view contains a range of frequencies, with
tendency for higher amplitudes at low frequencies and lower amplitudes at higher
frequencies. On the contrary, statistical noise (noise related to the finite number of
annihilation photon pairs contributing to each element in the profile) has a uniform
spectral appearance and contributes equally at all frequencies. Thus, the ramp filter
leads to degradation of signal-to-noise ratio (SNR) since higher frequencies are re-
sponsible for the finer details (rapidly changing activity, sharp edges, and so on) in a
reconstructed images. By modifying the reconstruction filter, it is possible to obtain
a trade-off between the SNR and spatial resolution of the reconstructed image. A
simple way to do this is to cut off the ramp filter at a frequency νcutoff < νmax. Other
methods foresee the use of apodizing windows multiplied by the ramp filter, resulting
in a reduced magnitude at high frequencies. This filtering avoids a sharp change in
the filter at the cut off frequency reducing the chances of introducing artifact into
the reconstructed images.
In the YAP-(S)PET Reconstruction tool, the cut-off frequencies value is auto-
matically set to the Nyquist frequency, but it is also possible to select the desired
cut off frequency. In the Image Reconstruction panel (see figure 5.17), the cut off
frequency expressed in pixel actually refers to pixel/FOV, that is in the typical fre-
quency expression pixel/mm. Besides the ramp filter, the following types of filter can
be chosen: Shepp-Logan [125], Shepp-Logan modified, Hann, Low Pass Cosine and
Noise. The mathematical expression of the used filters are:
Figure 5.18 shows the graphs of the filters implemented in the YAP-(S)PET Re-
construction tool. The values reported on the y-axis are multiplied by a constant
factor [126].
The FBP algorithm is fast and relative easy to implement, that is why it is the
most widely used reconstruction method in nuclear medicine. Nevertheless it does
not allow to take in account various physical aspects of the imaging system and data
acquisition, such as system geometries, detector properties, scattering evaluation,
attenuation correction and so on.
The Maximum Likelihood Expectation Maximization algorithm, since its
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Ramp: H(ν) = |ν|
Shepp-Logan: H(ν) =
2 νcut−off
pi
sin
( |ν|pi
2 νcut−off
)
Shepp-Logan modified: H(ν) =
2 νcut−off
pi
sin
( |ν|pi
νcut−off
)
Hann: H(ν) = 0.5 |ν|
(
1 + cos
piν
νcut−off
)
Low Pass Cosine: H(ν) = |ν| cos
( |ν|pi
2 νcut−off
)
Noise: H(ν) =
|ν|
0.01 + |ν| ln[3
2
exp(1 + |ν|2)]
Figure 5.18: Graphs of the filters implemented in the YAP-(S)PET Reconstruction tool
for the FBP reconstruction mode. The Spatial frequency expressed in pixel actually refers
to pixel/FOV, that is in the typical frequency expression pixel/mm. The values reported
on the y-axis (Weight) are multiplied by a constant factor [126].
introduction to the field of image reconstruction in 1982 by Shepp and Vardi [127],
remains the basis for the most popular statistical reconstruction method and has
provided the foundation for many other methods. Likelihood is a general statisti-
cal measure that is maximized when the difference between the measured and the
estimated projection is minimized. The Expectation Maximization (EM) maximizes
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likelihood under a Poisson data model. It implicitly treats the projection data as hav-
ing a Poisson distribution determined by the counting statistics in each projection
bin and thus takes into account the statistical noise of the data.
The reconstruction problem can be written as follows:
sj =
∑
i=1
Mi,jai (5.6)
where ai is the activity in an image pixel i and sj is the number of counts in
projection element j. The i-index runs on all the FOV pixels, while the j-index cov-
ers all the LORs. Mi,j is the matrix that provides the probability that gamma rays
emitted in the pixel i are detected in the projection element j. This matrix provides
the model of the imaging system correlating the positron emission and photon de-
tection. In theory, this matrix should include all the parameters to exactly describe
the tomograph: system geometry, detector properties, scattering evaluation, attenu-
ation correction, and so on. In ML−EM algorithm implemented in the YAP-(S)PET
Reconstruction tool, only the detection geometry is considered. The Mi,j elements
number is given by the product between the sinogram space and the number of pixels
that are used to divide the FOV. Since the Mi,j matrix has a size that does not allow
storing all the elements, the storage space was drastically reduced by considering
both the symmetry and the sparse properties of the probability matrix [128].
The ML−EM algorithm can be written as:
ak+1i =
aki∑
jMi,j
∑
j
Mi,j · sj∑
iMi,j · aki
(5.7)
The meaning of the terms in equation 5.7 can be better explained with reference
to figure 5.19 [129]. We start with an initial image guess a0 that is the entire im-
age set to a constant value. The first step of the ML−EM algorithm consists in (1)
forward projects the initial image guess into the projection domain. Then, (2) these
projections are compared with the measured projections, s. This forms a multiplica-
tive correction factor for each projection, which is then (3) backprojected onto the
image domain to obtain a correction factor for the initial image estimate. This image
domain correction factor is then (4) multiplied by the current image estimate and
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divided by a weighting term based on the system model to apply the desired strength
of each image correction factor. The new image estimate is now reentered in the al-
gorithm as the next image; the algorithm repeats itself while the estimate approaches
the maximum likelihood solution. When the estimate projetion data exactly equalize
the measured projection data sj (substituting from equation 5.6):
ak+1i = a
k
i (5.8)
and the image does not change any more. This never actually occurs in practice
because of noise in the data and approximations in Mi,j.
As the ML−EM algorithm iteratively guesses an image estimate, the low frequency
components of the image appear within the first few iterations. As the Maximum
Likelihood estimate is approached, more and more high frequency definition is re-
solved in the image, effectively adding more variance to the reconstruction. The
convergence rate of ML−EM is image dependent, but usually requires approximately
20-50 iterations to reach an acceptable solution [129].
In ML−EM algorithm implemented in the YAP-(S)PET, it is either possible to
freely choose the number of iterations to be performed during the reconstruction or
to set the automatic procedure that determine the number of iteration on the basis
of an empirical parameter [128].
Due to the possibility to include the detection process in the probability matrix
Mi,j, the ML−EM algorithm leads to potentially more accurate images. On the
other hand, the reconstruction time is considerably longer than the FBP approach.
A number of approximations have been developed to speed up these algorithms.
One of the most popular is the Ordered Subsets Expectation Maximiza-
tion (OSEM) introduced in 1994 by Hudson and Larkin [130]. With OSEM, the
projection data are grouped in subsets of projection views. Then, the ML−EM al-
gorithm is applied to the projections in the first subset and the obtained image is
used as starting image for the next subset. An iteration of OSEM is then defined as
a single pass through all the specified subsets. Further iterations may be performed
by passing through the same ordered subsets, using the reconstruction provided by
the previous iteration as a starting image. When there is only one subset, OSEM is
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the same as ML−EM. Even though OSEM resembles ML−EM, this computationally
convenient method is not guaranteed to converge to the ML solution. In practice, its
convergence is similar to ML−EM and approaches the ML solution roughly B times
faster than conventional ML−EM, where B is the number of subsets.
In the YAP-(S)PET Reconstruction tool, it is possible to choose up to six subsets
and a maximum of 1000 iterations for both ML−EM and OSEM algorithms. It is also
possible to choose the display of the reconstructed image of some of the intermediate
iterations, besides the last one.
Figure 5.19: Flow diagram of the ML−EM algorithm. Starting with an initial image guess
(a0) in the upper left, the algorithm iteratively chooses new image estimates based on the
measured projections, s [129].
Other reconstruction methods for the YAP-(S)PET scanner are under investi-
gation. In particular, a multi-Ray based system matrix generation for 3-D PET
reconstruction [131].
5.3.5 Display
The end result of the Reconstruction process is a 3-D image volume where each
individual voxel (volume element) represents the regional tissue radioactivity concen-
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tration.
The digital images so produced are saved in a proprietary raw data format (imm).
The matrix size of the transaxial cross-section images can be 64 × 64, 128 × 128 or
256 × 256 corresponding to a pixel dimension of 1.5 mm/2, 1.5 mm/4 or 1.5 mm/8
respectively (1.5 mm is the YAP crystal pitch). The number of slices in the axial
dimension can be 27 or 53, corresponding to 1.5 or 0.75 mm sampling, respectively.
The pixel depth is 32 bits (4 bytes) and the data are stored in memory with Little-
Endian byte order 1. Image data can also be saved in the DICOM (Digital Imaging
and Communications in Medicine [132]) standard format.
The images display and processing can be performed with various imaging soft-
wares provided with the YAP-(S)PET scanner: ImageJ, AMIDE and P-MOD
software.
The free and open source ImageJ [133] is a public domain Java image processing
program inspired by NIH (National Institute of Health [134]) Image for the Macintosh.
It has been developed by Wayne Rasband at the Research Service Branch of the NIH,
Bethesda, Maryland, USA. It can run virtually on all operating systems since it has
been written in Java 1.1. ImageJ is the imaging software embedded in the YAP-
(S)PET Analysis and Reconstruction tools and enables to automatically display both
sinograms and images.
AMIDE (Amide’s a Medical Imaging Data Examiner) [135] is a completely free
tool for viewing, analyzing, and registering volumetric medical imaging data sets. It
has been developed using GTK+/GNOME, and runs on any system that supports
the toolkit (Linux, Windows, Mac OS X with fink, etc.).
PMOD [136] is a proprietary software produced and commercialized by PMOD
Technologies Ltd., Zurich, Switzerland. It has been written in Java 2 and is currently
offered under Windows, Linux and MacOS X operating systems. PMOD consists of
a set of user-friendly and powerful tools, each corresponding to a major task. Among
the main tools, the general kinetic modeling contains a comprehensive set of models
for the analysis of time-activity data. The cardiac tool is tailored to assess function
1In computing, endianness is the byte ordering in computer memory used to represent data. In
the Little-Endian byte order the least significant byte (LSB) value is at the lowest address. The
other bytes follow in increasing order of significance.
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in cardiac segments by full kinetic modeling, and to compare the outcome against
normal databases. The image fusion tool does not only allow to register images, but
also enables the user to explore the calculated functional images in detail.
Chapter 6
Small animal imaging studies
This chapeter reports a few case animal studies performed within the CEIP, the
Center of Excellence in Preclinical Imaging located inside the Bioindustry Park Sil-
vano Fumero S.p.A. (see section 4.1). Of all the studies performed, the three most
representative have been choose, in particular:
• a longitudinal imaging study of the response to Dasatinib treatment in PC-
3 prostate tumor-bearing nude mice assessed by 68Ga-AMBA and 18F-FDG.
This is a PET study was perdormed under a contract drawn up by the Bracco
Research USA Inc and Ephoran company. In this contract Ephoran carried out
is Service Company role, while the pratical work was performed in collaboration
by the personnel of the University of Torino working at CEIP, the Advanced
Acceletator Applications and the Bracco Imaging S.p.A.
• a longitudinal study concernig the Evaluation of the 99mTc-rhAnnexin V-128
imaging effectiveness for diagnosis and monitoring anti-rheumatic therapies in
a collagen induced arthritis model in mice. This SPECT study was carried out
within a collabroation between the AAA and the the personnel of the University
of Torino working at CEIP.
• a PET/MRI study to test the co-registration capabilities of and home-made
PET/MRI compatible bed. This multimodality studies was carried out within
a collaboration between the the personnel of the University of Torino working
at CEIP and the Division of Neuroscience, INSPE of the San Raffaele Scientific
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Institute. The employed radiotracer (18F-FDG) was supplied by AAA company.
6.1 Response to chemotherapy in prostate tumor-
bearing mice
Prostate cancer (PC) is the most frequently diagnosed cancer (25%, 192280 cases) and
the second-leading cause of cancer-related deaths (9%, 27360 deaths) for males in the
US [137]. As long as the prostate cancer is organ-confined, prostate surgery or radia-
tion therapy with curative intent is the first choice of treatment. However, when facing
metastasized PC, curative treatment is no longer available and palliative hormone ab-
lation therapy is indicated. Therefore, accurate staging of early prostate cancer at the
time of diagnosis as well as monitoring of patients following local or systemic treat-
ment are crucial steps in the management of the disease [138]. Conventional (anatom-
ical, structural) imaging is insensitive to the presence of cancer, often failing to yield
the information needed for accurate diagnosis and staging, for proper treatment selec-
tion and monitoring or for effective follow-up after treatment [139]. New non-invasive
sensitive imaging strategies to accurately diagnose, stage and monitor PC are there-
fore required. Radiolabelled peptide-based imaging by scintigraphy - single positron
emission tomography (SPECT) or positron emission tomography (PET) - may be
an interesting alternative [138]. In fact, specific biological changes in tumors may
occur within hours to days of pharmacological treatment and precede clinical signs.
Therefore imaging biomarkers able to assess the most relevant molecular events may
be highly suitable to detect early responses and predict treatment outcome. A poten-
tial imaging biomarker has been identified in the Gastrin-Relasing peptide receptor
(GRP-receptor) which is often found to be overexpressed in proliferating cancer cells.
Moreover, the GRP/GRP-R system is a growth factor for tumors and has been shown
to promote angiogenesis in animal tumor models - which is thought to be necessary
for tumor growth and to indicate more aggressive tumors. The role of bombesin-like
peptides, and especially of GRP and its interaction with the GRP-R, in promoting
tumor growth in human cancer cells both in culture and in nude mice xenografts
has been established by numerous studies [140]. Most interestingly, the expression of
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GRP-Rs has been documented in several frequently occurring human cancers, such
as in prostate and breast carcinomas [141, 142]. Bombesin-like peptides have been
employed as molecular carriers of cytotoxic drugs or diagnostic/therapeutic radionu-
clides to GRP-R-expressing tumors for diagnosis and therapy. For this purpose,
agonists are usually preferred, due to their tendency to rapidly internalize after bind-
ing to their receptor resulting in increased target accumulation [140]. In this study
we tested a Gallium-chelated bombesin-related peptide agonist: DO3A-CH2CO-G-
4-aminobenzoyl-Q-W-A-V-G-H-L-M-NH2, (AMBA). AMBA is a bombesin analogue
which has shown good targeting performance in (pre)clinical studies [143, 144]. It is
coupled to the DOTA chelator which enables labelling with 68Ga, a positron emitting
radionuclide suitable for PET, resulting in 68Ga-DOTA-AMBA (68Ga-AMBA). Apart
from peptide receptor-based targeting, metabolism based tracers are also being used
to image cancer cells. Metabolic targeting is based on the assumption that cancer
cells show increased activities of several metabolic processes [145], and indeed, malig-
nant transformation of cells has been found to be associated with increased metabolic
activity [146]. In this preclinical investigation, we evaluated 2-deoxy-2-[18F]fluoro-
D-glucose (18F-FDG) and 68Ga-AMBA as biomarkers of the response to Dasatinib
treatment in prostate tumor-bearing nude mice (xenograft, PC-3). The animal model
of choice was the prostate tumor xenograft in mice since the GRPR-expressing cell
line PC-3 (human prostate adenocarcinoma cells) is the most widely used model for
the study of radioactive bombesin analogues [147–149]. Dasatinib (BMS-354825) is
a novel, orally available multi-targeted kinase inhibitor against BCR-ABL that is
several fold more potent than imatinib, and also potently inhibits imatinib-resistant
BCR-ABL mutants [150–152]. Dasatinib also potently inhibits SRC kinase, a recep-
tor tyrosine kinase that plays a critical role in the development, growth, progression,
and metastasis of a number of human cancers [143, 144] and [150–152] and has been
shown to inhibit proliferation, cell adhesion, migration and invasion of prostate can-
cer cells in vitro [152]. It has been tested in clinical trials for prostate cancer [153]
and results are promising [154], however, dosing is not easy and attempts have been
made to develop a pharmacodynamic biomarker [155].
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6.1.1 Materials and methods
Tracer
The production of the radiopharmaceutical tracer 68Ga-AMBA was performed by
using the Taddeo automated synthesis module (Comecer) after Cagnolini et al [156].
The synthesis was carried out by adding in a reactor 1 mL of Ga-68 eluate obtained
using a 68Ge/68Ga generator (Eckert and Ziegler) eluted with 0.1N HCl to 100 µL of
AMBA formulation (12 µg of AMBA). 200 µL of an NaOAc solution 1 are introduced
in the reactor to provide the additional buffering required to obtain a pH suitable
for the coordination of Ga-68 with DOTA. The reaction mixture is heated at 95 oC
for 7 minutes, cooled to 30 oC and then loaded onto a C18 Sep-Pak Light cartridge
that was previously conditioned with 3 mL of EtOH and 8 mL of H2O. To increase
recovery, the reactor was rinsed with 2 mL of 90% H2O/10% EtOH and the rinse
solution loaded on the Sep-Pak. The Sep-Pak was then washed with 4 mL of H2O
to elute any potential 68Ge breakthrough and hydrophilic impurities. 68Ga-AMBA
was then eluted into the product vial with 500 µL of EtOH. After product recovery,
150 µL of a 9:1 saline: Ascor solution were added and the ethanol was evaporated by
heating under nitrogen flow.
The radiochemical purity (RCP) was assessed by analytical HPLC using a Zorbax
Bonus-RP column (4.6 × 250 mm; 5 µm, Agilent), a flow rate of 1 mL/min and as
eluent a mixture of H2O + 0.1% TFA [A] and ACN + 0.1% TFA [B] (gradient of
[B] from 17 to 40% in 20 minutes. The results show an average RCP of 95% and a
radiochemical yield of 20-50%.
Cell Culture
PC-3 (human prostate adenocarcinoma) cells were obtained from the American Type
Culture Collection (ATCC). PC-3 cells were cultured in Hams F-12 medium supple-
mented with 10% foetal bovine serum, 2 mM glutamine, 100 IU/mL penicillin and
100 µg/mL streptomycin.
1Preparation of sodium acetate solution: a diluted NaOAc solution was prepared by premixing
320 µL of the 164 mg/mL NaOAc solution (Hospira), and 480 µL of H2O in a 2 mL vial.
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In vivo studies
All animal studies were performed according to the guidelines for the care and use
of research animals and were approved by the local ethics committee. Twenty NCR
nu/nu Athymic nude male mice 5 weeks old (average weight 20 g) were used (Har-
lan Italy). Five million PC-3 cells were suspended in 0.1 mL PBS and injected
subcutaneously in the right flank. The mice were housed in Makrolon R© Tecniplast
ventilated cages fitted with Yelu R© HW 300/500 sterilized bedding material, supplied
by Charles River and certified as being without contaminant in toxic concentrations.
Cage changes occurred twice per week. Sterile rodent chow (4RFNSTER pelleted diet
produced by Mucedola, Settimo Milanese) and sterile filtered water with 3 mL/L of
Gentamicin Sulfate (50 mg/mL) added, were provided ad libitum. During the entire
period of the study the animals were housed in a cabinet with conditioned environ-
ment.
Tumors measurement started four days after cells inoculation and the tumor vol-
ume, V, was calculated according to the formula: V = 1/2 L×W2, where L and W are
the major and orthogonal axis of the tumor, respectively. Three weeks after tumors
inoculation, the mice were divided in two groups: the control (n=8) and the treated
one (n=8). The mice assigned to the treatment group underwent PET imaging and
Dasatinib treatment and were chosen on the basis of tumor caliper measurements.
Dasatinib preparation and treatment
Dasatinib was supplied as a solid powder. A mixture of Propylene Glycol and sterile
dH2O (1:1) was emulsified for thirty minutes with an IKA Ultra Turrax T8/T8.01
Homogenizer at rotation speed 2 on a scale from 1 to 6 corresponding to a speed
range from 5000 to 25000 revolutions min−1. The Dasatinib powder was then added
and emulsified for 3.5 hours with the homogenizer at rotation speed 5 to obtain a
final concentration of 15.4 mg/mL of the drug. (The quantity of Dasatinib solution
administered was around 100 µL for a 30 g mouse). The emulsion was then stored in
a refrigerator.
The Dasatinib formulations were prepared weekly. The stability of the drug under
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the storage conditions was verified by MALDI analysis on a solution sample one week
old. The MALDI analysis was performed on a sample of 15.4 mg/mL of drug concen-
tration that was mixed 1:1 with a saturated solution of a-cyano-4-hydroxycinnamic
acid in 70% acetonitrile and 0.2% TFA and 0.5 mL was spotted directly on a MALDI
target plate. MALDI mass spectra were acquired in the positive reflection ion mode
with delayed extraction on an Ultraflex II TOF-TOF instrument (Bruker Daltonics,
Bremen, Germany) equipped with a 200 Hz all-solid-state laser. Ion acceleration
voltage was set to 25.00 kV, the reflector voltage was set to 26.30 kV and the first
extraction plate was set to 21.75 kV. Mass spectra were obtained by averaging 1000
laser shots in a mass range of m/z 400-1000. A ready-made peptide standard (Bruker
Daltonics) was used for calibration of spectra. There was good correspondence be-
tween the main peak of the spectrum (see figure 6.1 and the Dasatinib mass of 488.01
Dalton reported in the Certificate of Analysis of the Dasatinib supplier [157].
Figure 6.1: MALDI analysis of a Dasatinib solution one week old.
Dasatinib treatment started the day after 68Ga-AMBA scan #1 (see figure 6.2):
a dose of 50 mg/kg Dasatinib was administered orally, daily, 5 days on / 2 days
off [152,155]. This treatment went on till the second 18F-FDG, i.e., about four weeks.
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After this period, the Dasatinib treatment was reduced to a dose of 25 mg/kg and
administered daily, 5 days on / 2 days off [158].
Figure 6.2: Timeline of the experimental procedures.
PET imaging
The PET experiments were performed with a YAP-(S)PET scanner (see chapeter
5). The timeline of the experimental procedures is reported in figure 6.2. The first
PET scan was performed with 18F-FDG when the tumor size was around 200 mm3.
The first 68Ga-AMBA PET scan (scan #1) was performed within ten days from the
18F-FDG. The day after 68Ga-AMBA scan #1 the Dasatinib treatment at a dose
of 50 mg/kg started. 68Ga-AMBA scan #2 and scan #3 were performed two and
four weeks after Dasatinib treatment start, respectively. A second 18F-FDG scan was
performed within two days of 68Ga-AMBA scan #3. The last 68Ga-AMBA scan (scan
#4) was performed four weeks after the 68Ga-AMBA scan #3, close to the end of the
Dasatinib treatment at the dose of 25 mg/kg. According to Fueger et al. [159], all the
animals were fasted for 12-14 hours before 18F-FDG tracer injection. A mean value
of 11.4 ± 1.7 MBq (300 µCi) of 18F-FDG was injected i.v. in a volume of around 0.3
mL and the PET imaging started after forty-five minutes of uptake.
Animals were not fasted before 68Ga-AMBA injection. A mean value of 13.0 ± 1.8
MBq (350 ± 50 µCi) of 68Ga-AMBA was injected i.v. in a volume of ∼ 0.3 mL and
the PET imaging started after sixty minutes of uptake. For both 18F-FDG and 68Ga-
AMBA PET imaging, the animals were warmed with a heating pad (30 oC) for at
least thirty minutes before tracer injection. During both the uptake and imaging time
the animals were kept under anesthesia with Isofluorane gas and Oxygen: anesthesia
was maintained by adjustment of the gas level as a function of breathing rate. Only
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the part of the body within four centimeters and centered on the tumor was acquired
with the PET scan.
Static PET data were performed in 3-D mode (without septa) by acquiring 80
M events for 18F-FDG or 40 M events for 68Ga-AMBA and the data were stored in
list mode binary format. Once acquired, the data were reorganized by a Single Slice
Rebinning Algorithm (SSRB) with a maximum span fixed to eleven Line of Response
(LOR) and sinograms were reconstructed with a Maximum Likelihood Expectation
Maximization (ML-EM). The result of the Reconstruction process was a 3-D image
volume, where each individual voxel (volume element) represents the regional tissue
radioactivity concentration.
For semi-quantitative evaluation, data from a 63 mL c ylinder phantom filled
with 18F or 68Ga (about 7.4 MBq, 0.2 mCi) was acquired on the PET scanner and
reconstructed with the same protocol used for the animal studies. From this scan, a
system calibration factor was calculated by dividing the known activity concentration
in the phantom by the measured mean counts per voxel in the reconstructed PET
images. The calibration factor was used to convert the raw counts measured by the
scanner into activity concentration.
Regions of Interest (ROIs) were manually drawn over the tumors to evaluate
18F-FDG and 68Ga-AMBA uptake. Tracer uptake of tumors at different stages was
corrected for decay and quantified by using the percentage injected dose per gram of
tissue (%ID/g), accordign to the following equation:
%IDg = CT
VT
WT
1
Dinj
· 100 (6.1)
where
• CT is the radioactivity in the ROI with the unit of mCi/ml tissue.
• WT (in g) and VT are the weight and the volume of the considered organ,
respectively, and their ratio gives the density of the region. The density of
tissue is assumed to be 1 g/mL.
• Dinj is the injected dose of radiotracer with the unit of mCi. The %ID/g of a
tissue represents the percent of the injected dose activity present in a gram of
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tissue and it is a way of normalizing the signal imaged at a given location to
the amount of tracer injected into the subject [122].
6.1.2 Results
The effect of therapeutic regimens on PC-3 tumor bearing mice was evaluated on
tumor growth by caliper measurements. 18F-FDG and 68Ga-AMBA PET imaging
evaluated the effect of Dasatinib treatment on metabolic activity and on GRP recep-
tors expression, respectively.
Tumor growth
The results of the treatment on tumor growth are reported in figure 6.3.
Figure 6.3: Tumor growth curve for each of the twenty mice involved in the study: the
control group in red and treated one in green.
Before the Dasatinib treatment start, the tumor volumes of both groups (control
and treated) were comparable. After the first week of treatment, two different behav-
iors can be highlighted. In all the mice treated with Dasatinib at a dose of 50 mg/kg
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(green lines), the tumors maintained approximately the same volume (i.e. the tumor
growth was inhibited); in the control group (red lines) the tumors continued growing
almost exponentially. The switch to 25 mg/kg in Dasatinib treatment let the tumors
restart growing almost exponentially as the ones of the control group.
PET imaging
Figure 6.4 highlights that PC-3 tumors can be positively imaged, with good tumor-
to-background contrast, by using 68Ga-AMBA.
Figure 6.4: Coronal section of the slice containing the tumor. (A) 68Ga-AMBA scan #1,
before the start of the Dasatinib treatment. (B), (C) e (D) 68Ga-AMBA scan #2, #3 and
#4: two, four weeks and one month after the start of the Dasatinib treatment, respectively.
Comparison between the image of the first 18F-FDG (figure 6.5A) and the 68Ga-
AMBA images (figure 6.4) also showed that 68Ga-AMBA has a higher uptake than
18F-FDG in PC-3 tumors. Visual results on the images are supported by the semi-
quantitative analysis on ROI taken on the tumors of each animal (see table 6.1).
Figure 6.6A reports the percentage change of 68Ga-AMBA uptake before and after
the Dasatinib treatment at a dose of 50 mg/kg. Three different trends were observed
on mice after treatment start: positive slope (red lines), negative slope (green lines)
and lack of slope (orange and dark green lines). We supposed that the slope trend
might predict a response to treatment. In particular: positive and negative slopes
might predict negative and positive response to Dasatinib treatment, respectively,
while the lack of slope might equally predict a response to treatment.
To validate these hypotheses, the Dasatinib treatment was prolonged over the
foreseen four weeks. Since the mice were weakened and have experienced an average
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Figure 6.5: (A) Coronal section of the slice containing the tumor. (a) and (b): first
and second 18F-FDG scan, before the start of the Dasatinib treatment and one month after,
respectively. (B) Percentage of %ID/g change in 18F-FDG uptake before and after Dasatinib
treatment at 50 mg/kg.
Figure 6.6: (A) Percentage of %ID/g change in 68Ga-AMBA uptake before and after
Dasatinib treatment at 50 mg/kg. (B) Percentage of %ID/g change in 68Ga-AMBA uptake
before and after Dasatinib treatment at both 50 and 25 mg/kg.
body weight loss of about 15% from the beginning of treatment, it was decided to
reduce the Dasatinib dose to 25 mg/Kg, daily, 5 days on / 2 days off. As shown in
Figure 3, the 25 mg/kg Dasatinib treatment was not able to produce tumor growth
cessation and the low dose did nearly not affect the 68Ga-AMBA slope trend apart
from animal “C01” that exhibits a change from a positive to a negative slope (see
figure 6.6B). Figure 6.6B reports the percentage change in 18F-FDG uptake before
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and after Dasatinib treatment at 50 mg/kg. The uptake of 18F-FDG was comparable
pre and post treatment. Figure 6.7 reports the comparison between the Kaplan-Meier
curves of the untreated mice group (red line) and the treated one (green line).
Figure 6.7: Comparison of the Kaplain-Maier curves of the untreated mice group (red line)
and the treated one (green line)..
The analysis of the survival curves pointed out that the Fractional survival of
the mice treated at the Dasatinib dose of 50 mg/kg increased about 30% over the
untreated mice. The switch in Dasatinib treatment to 25 mg/kg led to an increase
of the Fractional survival curve of the treated mice up to 60%: nevertheless the
treatment at half dose was not able to stop the tumor growth (see figure 6.3).
6.1.3 Discussion
Development of non-invasive methods such as PET to evaluate the therapeutic re-
sponse of solid tumors like prostate cancer, is of great interest for clinical investi-
gation. In fact, it could allow investigation of the individual response to treatment
in a quick, repetitive and accurate way. 18F-FDG is the most widely used radioac-
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%ID/g
Animal First 68Ga-AMBA 68Ga-AMBA 68Ga-AMBA Second 68Ga-AMBA
ID 18F-FDG scan #1 scan #2 scan #3 18F-FDG scan #4
N01 3.1 ± 0.6 7.0 ± 1.4 4.5 ± 0.9 -
R02 2.4 ± 0.5 6.9 ± 1.4 5.8 ± 1.2 6.4 ± 1.3 3.3 ± 0.7 6.5 ± 1.3
L02 2.8 ± 0.6 6.6 ± 1.3 6.4 ± 1.3 4.5 ± 0.9 3.8 ± 0.7 3.7 ± 0.7
L03 3.2 ± 0.6 4.8 ± 1.0 4.8 ± 1.0 4.7± 0.9 2.3 ± 0.6 2.4 ± 0.5
N04 3.4 ± 0.7 7.3 ± 1.5 5.1 ± 1.0 4.1 ± 0.9 3.2 ± 0.7 1.9 ± 0.4
A04 3.3 ± 0.6 6.6 ± 1.3 5.1 ± 1.0 5.0 ± 1.0 3.3 ± 0.7 4.8 ± 1.0
C01 4.1 ± 0.8 5.4 ± 1.1 7 ± 1.4 7.2 ± 1.4 3.5 ± 0.8 2.6 ± 0.52
L01 2.4 ± 0.5 5.4 ± 1.1 7.2 ± 1.4 7.9 ± 1.6 2.1 ± 0.5 -
Table 6.1: %ID/g of the 18F-FDG scan#1 and #2 and of the 68Ga-AMBA scan #1 through
#4 with relative errors calculated in the tumors of each animal.
tive tracer in oncology due to its capability to detect a wide variety of tumor foci.
However, the applicability of 18F-FDG-PET in imaging of prostate cancer has not
been convincingly demonstrated because of the low metabolic activity of this type
of cancer [160]. Liu and collaborators did not find 18FDG-PET useful in the evalua-
tion of clinically organ-confined prostate cancer [161], and Salminen and co-workers
suggested that PET scanning in prostate cancer demonstrates variable metabolic ac-
tivity [162]. These findings led us to combine the use of 18F-FDG with 68Ga-AMBA in
the tumor visualization and uptake evaluation of a mouse model of human prostate
cancer (PC-3 xenografted). Among other possible PET prostate tracers, like 11C-
Choline [163], we chose 68Ga-AMBA since AMBA is a new molecule, highly specific
for the GRP receptors [164] over-expressed in prostatic tumors and moreover has been
successfully used for imaging [165]. Our studies confirmed the efficacy of 68Ga-AMBA
for GRP-R imaging since, on average, the %ID/g of the tumor with 68Ga-AMBA was
twofold higher than 18F-FDG.
In order to be able to develop imaging biomarkers for prediction of response
it is necessary to use appropriate animal models which in this case should have a
dynamic range of responses to treatment such as tumor growth curves or survival.
Our control animals had such a dynamic range in their tumor growth characteristics.
However, although a 50 mg/kg treatment produced a prompt cessation of tumor
growth, it produced limiting body weight loss and reduced the variability in tumor
growth curve characteristics over the 4 weeks of treatment that were investigated
at this dose. The dose used was based on literature doses from studies designed to
demonstrate an unequivocal beneficial response. We believe the dose is too high and
reduced the dynamic range of the response experienced using clinically acceptable
120 Chapter 6. Small animal imaging studies
doses in humans. On the other hand, the switch to 25 mg/kg treatment later in
the study was not able to produce tumor growth cessation (see figure 6.3) perhaps
because the earlier use of a high dose had selected for resistant cells in the tumor.
We saw significant changes in both the 68Ga-AMBA and 18F-FDG signal from
a given tumor after treatment. These changes were positive and negative relative
to the initial scan and there was no correlation between the sign or magnitude for
68Ga-AMBA or 18F-FDG. The slopes of the percentage change in 68Ga-AMBA after
Dasatinib treatment at 50 mg/kg where essentially unchanged by the switch to 25
mg/kg apart for animal “C01” (see figure 6.6). Given the wide dynamic range of the
68Ga-AMBA or 18F-FDG signal after treatment but the narrow dynamic range of the
tumor growth response due to the dose given, as described above, we were unable to
correlate the two. Summarizing, the observed antitumoral effects of Dasatinib at the
dose of 50 mg/kg can be predicted neither by the 68Ga-AMBA nor by the 18F-FDG
imaging since the chemotherapeutic dose was too high and concealed any potential
differences in response.
6.1.4 Conclusion
The data presented illustrate that molecular imaging with 68Ga-AMBA can accu-
rately visualize prostate tumors in this xenografted mouse model (PC-3) and has a
higher uptake (twofold) with respect to 18F-FDG. The Dasatinib treatment doses used
(50 and 25 mg/kg) did not allow correlation to treatment changes using 68Ga-AMBA
or 18F-FDG. We concluded that animal dosing for longitudinal imaging studies needs
to be less than the one used for therapy development studies (50 mg/kg) to achieve a
wider dynamic range of animal response similar to the clinical situation For further
studies on PC-3 bearing tumors mice, we believe that the use of a Dasatinib dose be-
tween 25 and 50 mg/kg may be able to produce a correlation between the treatment
response and the 68Ga-AMBA uptake.
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6.2 Monitoring anti-rheumatic therapies in an arthri-
tis mouse model
Rheumatoid arthritis (RA) is a chronic inflammatory and destructive joint disease.
Approximately, 1 % of the population in the industrialized world is affected by the
disease. There is a slight gender imbalance, with two to three times more women
affected than men. The peak onset occurs between the fourth and the sixth decade.
Despite intense research in this field, there is ongoing controversy over the etiological
agent causing RA. It is still unclear wheter it is a primarily autoimmune response re-
flecting an imbalance in the immune regulation or primarily an inflammatory response
to an external stimulus, eihter mechanical or microbial. There is evidence support-
ing both theories, and it may well be that it is a combination of both autoimmune
disease and inflammatory disregulation. This apparent complexity is reflected in the
heteregeneous clinical presentation of RA. However, once the disease is initiated, RA
has a homogeneous course of joint destruction with well-defined end-stage effectors:
massive macrophage and neutrophil infiltration, tumor necrosis factor /TNF)-α, and
interleukin-1 (IL-1) secretion and upregulation of degenerative probes [166]. Thus,
RA may lead to impairment and entually complete loss of joint function. Combined
with chronic pain, these factors seriously interfere with patients qualitiy of life.
T lymphocytes (or simply T-cells) constitute the first clear defined and investi-
gated step in the initiation of RA. In an inflammed synovium of RA, T cells represent
a considerable proportion of the cellular mass. Up to %50 of all cells are T cells. In-
terestingly, there are differences between T cells of healthy control and RA patients.
RA patients have a large pool of autoreactive T-cell clones in the thymus that once
they arrive in the joint and are activated amplify the inflammatory response. The
T-cells often induce apoptosis of target tissue before their own apoptotic cell death.
Apoptosis is programmed cell death, an essential process for normal development
and function of tissue. Dysregulation of apoptosis is associated with a variety of dis-
eases, either leading to excessive cell proliferation, e.g., in malignancies, or increased
cell death as found in neurodegeneration, tissue ischemia, immunological disorders
(e.g., transplant rejection), and autoimmune diseases [5]. In RA, both invading im-
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mune cells and resident cells are prone to apoptosis. Wheter the amount of apoptosis
seen is appropriate, too high, or too low, is a matter of cntroversial debate. Certain is
the intimate involement of apoptotic events in the course of RA. Several studies have
indicated that there is an increase in apoptotic cell death in the synovial membrane
in RA [167, 168]. Therefore, determining the presence and the degree of apoptotic
cell death in affected joints and periarticular tissues may prove crucial for both the
study and the clinical evaluation of RA [169]. Annevin V is a marker of apotosis.
It binds phosphatidylserine, a phospholipid that under physiological consitions are
rstricted to the inner leaflet of the cell membrane lipid layer. Upon apoptosis, phos-
phatidylserine si flipped to the outside of the cell membrane, where it can be detected
by Annexin V (see figure 6.8).
Figure 6.8: Apoptosis expression of the phosphatidylserine. On the left: normal mem-
brane translocase and floppase activity. On the right: translocase and floppase inactivated,
scramblase activated. .
The aim of this study is to investigate the 99mTc-rhAnnexin V-128 as in vivo
apoptosis imaging marker to diagnose and monitor the response to anti-rheumatic
therapies in a collagen induced arthritis (CIA) mice model. CIA is a widely used
model system to study arthtitis since it resembles the human disease in many featires,
immulogical and pahtological. The method of induction of CIA has been adapted
from the protocol published in [170].
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6.2.1 Materials and Methods
Mice immunization
All animal studies were performed according to the guidelines for the care and use of
research animals and were approved by the local ethics committee. Twenty DBA/1
male mice were immunized by injecting intradermally at the base of the tail 0.2 ml of
an emulsion containing 0.4 mg of bovine type II collagen in Complete Freund’s Adju-
vant (CFA, Difco, Detroit, U.S.A.) containing 0.4 mg of Mycobacterium tuberculosis.
Immunization with CFA+CII resulted, starting approximately from day 18-20 post
immunization (PI), in the appearance of inflammation signs affecting one or more
limbs.
Clinical observations
Starting from day 18, animals were individually graded for disease severity by means
of a clinical score (CS) composed as follows: a) Visual clinical score (VS) for the
presence of inflammation in the fingers of the forepaws and hindpaws:
0 = no sign of disease.
0.5 = from 1 to 5 fingers/toes with signs of inflammation.
1 = from 6 to 10 fingers/toes with signs of inflammation.
1.5 = from 11 to 15 fingers/toes with signs of inflammation.
2 = from 16 to 20 fingers/toes with signs of inflammation.
b) Clinical swelling score for the presence of paw edema in the forepaws and hind
paws. Forepaws and hindpaws were measured daily for paw thickness by means of a
precision caliper.
Forepaw:
0 = no sign of disease (paw thickness up to 1.29 mm).
0.5 = paw thickness between 1.30 and 1.59 mm.
1 = paw thickness between 1.60 and 1.89 mm.
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2 = paw thickness between 1.90 and 2.20 mm.
3 = paw thickness > 2.20 mm.
Hindpaw:
0 = no sign of disease (paw thickness up to 1.99 mm).
0.5 = paw thickness between 2.00 and 2.19mm.
1 = paw thickness between 2.20 and 2.59 mm.
2 = paw thickness between 2.60 and 3.00 mm.
3 = paw thickness > 3.00 mm.
The maximum swelling score (SS) per animal is therefore 12 when all the four
paws arise the score 3.
The sum of the two separate clinical scores (CS and SS) generated a total clinical
score (CS):
CS = VS + SS (6.2)
Observation of the animals took place in a quiet room.
SPECT studies
SPECT studies were performed to investigate the 99mTc-rhAnnexin V-128 (99mTc-
AxV) as in vivo apoptosis imaging marker to monitor the response to anti-rheumatic
therapies in the CIA mice model.
The mice were divided in three groups: PBS, INDO e NAÏVE. The PBS group
(n=6) received daily a phosphate buffered saline (PBS) by intraperitoneal (i.p.) in-
jection, the INDO group (n=6) received daily a dose of 2 mg/kg of indomethacin,
while the mice belonging to the NAÏVE group (n=6) were not immunizated and did
not receive any treatment. Treatment started at CS ≥ 1.5 and lasted 10 days.
rh-Annexin V-128 was produced in E. coli. Purified protein properly formulated
was labeled with 99mTc-pertechnetate and injected within 1 hour from the labeling
(protein provided by Atreus Pharmaceuticals Corporation [171]).
6.2. Monitoring anti-rheumatic therapies in an arthritis mouse model125
Treated animals with both PBS and INDO were monitored by SPECT scans at
day 2, 4 (onset), 9 and 10 (end of treatment) post recruitment, (pr). NAÏVE mice
were used as reference and scanned only once. 99mTc-AxV was administered by i.v.
injection and two separate static scans were performed, since the SPECT scanner
used has a 4 cm FOV (see chapter 5). A first scan, focused on the front paws was
performed 1 hour after 99mTc-AxV injection and a second scan focused on the rear
paws after 2 hours. 4 and 2.5 Mevents were acquired, respectively. 99mTc-AxV
paws uptake was expressed as %ID/g (see equation 6.1). Once acquired, the data
were reorganized by a SSRB Algorithm with a maximum span fixed to eleven Line
of Response (LOR) and sinograms were reconstructed with a ML-EM. The result
of the Reconstruction process was a 3-D image volume, where each individual voxel
(volume element) represents the regional tissue radioactivity concentration. For semi-
quantitative evaluation, data from a 63 mL cylinder phantom filled with 99mTc (about
185 MBq, 5 mCi) was acquired on the SPECT scanner and reconstructed with the
same protocol used for the animal studies. From this scan, a system calibration
factor was calculated by dividing the known activity concentration in the phantom
by the measured mean counts per voxel in the reconstructed SPECT images. The
calibration factor was used to convert the raw counts measured by the scanner into
activity concentration. ROIs were manually drawn over the fore and rear paw pads.
6.2.2 Results
Disease worsening in PBS group mice was confirmed by the CS and paw thickness
increase (about 30%) between the first and the last day of treatment; while disease
amelioration induced by treatment with INDO was reflected by significant reduction
of CS and paw thickness (see Figure 6.9).
99mTc-AxV uptake was in accordance with CS variations. The %ID/g of the PBS
group increased during the disease progression, reaching a 2-fold value respect to
NAÏVE group at the time of maximum disease severity. On the contrary, in the
INDO group the uptake variation was not significant and the value was close to the
NAÏVE one (see Figures 6.10 - 6.12).
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Figure 6.9: Daily clinical score variation (on the left) and paw thickness variation (on the
left). ◦p<0.05; ◦◦p<0.01; ◦◦◦ p<0.001 two-way ANOVA followed by Bonferroni’s test.
Figure 6.10: Uptake of 99mTc-Annexin V-128 in Male DBA/1 mice, 9 days post recruitment.
Top: rear paws at days 2 and 9 pr (first and second raw) of a PBS treated mouse. Bottom:
rear paws at days 2 and 9 pr (first and second raw) of a Indomethacin treated mouse.
6.2.3 Conclusions
These findings suggest that the 99mTc-rhAnnexin V-128 can be used as an imaging
marker to follow disease status in the collagen-induced immune arthritis and to mon-
itor anti-inflammatory therapy effectiveness to indomethacin treatment. The clinical
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Figure 6.11: %ID/g in PBS (left) and INDO treated CIA mice (right) at onset (day 4 pr)
and end of treatment (day 10 pr).
Figure 6.12: %ID/g in PBS treated (left) and INDO treated CIA mice (right) at day 2 and
9 post recruitment (repeated experiment).
score of Indomethacin-treated mice decreases in accordance to the severity of inflam-
mation. Nevertheless the 99mTc-rhAnnexin V-128 uptake does not change probably
because the apoptosis rate is not affect by the treatment.
6.3 PET/MRI multimodality study
Positron Emission Tomography (PET) provides excellent sensitivity and specificity to
track biomolecules labeled with a radioactive isotope. Nevertheless the poor spatial
resolution hampers the quantification issues, especially in small animal imaging. To
overcome this limit, PET has to be associated to an anatomical imaging technique,
such as Computed Tomography (CT) or Magnetic Resonance Imaging (MRI). This
combined information simplifies the navigation within the reconstructed images al-
lowing an easier definition of the regions of interest (ROIs) thus fostering an improve-
ment in the quantification of radiotracer uptake [172]. Since 1990’s two approaches
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were followed in multi-modalities image combination: software and hardware. The
software approach is based on algorithms that retrospectively align 3-dimensional
(3D) data acquired by stand-alone modalities to common spatial coordinates [173].
The hardware approach physically integrate two different modalities scanner: the
alignment of the two images can then be guarantee by the hardware device. Since its
recent clinical introduction [174, 175], it was evident that the hardware integration
of PET/CT systems was superior to PET and CT stand alone scanners and could
have significantly improved the diagnostic and the therapeutic management. The
PET/CT combined scanners had a so wide spread, that last decade could be roughly
summarized as the PET/CT era [175]. Following the clinical success, PET/CT scan-
ners have been developed also for preclinical imaging and their diffusion increased
in the last years. Although PET/CT is already an established clinical tool and is
increasingly spread in preclinical research, it still bears some limitations. A major
drawback is that CT provides only limited soft tissue contrast and exposes the pa-
tient or animal under analysis to additional radiation dose [176]. Under this point
of view, PET combined with MRI is a suitable solution, not only for the absence of
ionizing radiation in MRI but also for its excellent soft-tissue contrast, and its capabil-
ity to provide complementary functional imaging [177]. Unlike PET/CT, PET/MRI
integrated scanners started out from developments in small-animal imaging tech-
nology [178] in the early 1990’s, some time before PET/CT became commercially
available. In contrast to PET/CT, where the two imaging components are attached
back-to-back and linked through a common patient table, PET/MRI approaches were
usually targeted to integrate the PET technology inside the MRI system, matching
both fields of views (FOVs) [172]. However, the installation of a PET insert inside an
MRI scanner is challenging due to mutual electromagnetic interferences [179]. The
strong static magnetic field, the switching of magnetic gradients and use radiofre-
quency (RF) from MRI are incompatible with the sensitive PET detectors. And
vice versa, the PET detectors can significantly disturb the homogeneity of the main
magnetic field. Based on these restrictions, the development of MR-compatible PET
detectors has been a topic of intensive research for more than 15 years [172]. In the
same period, several co-registration algorithms, especially in functional brain imag-
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ing studies were developed [2, 9]. The attempt in manufacturing hybrid PET/MRI
systems has been based on the use of MRI-compatible PET components, in order to
allow simultaneous PET and MRI data acquisitions, but these apparatus are still un-
der development and very expensive. In preclinical imaging centers where both MRI
and PET systems are available, dedicated algorithms for image co-registration have
been developed, however misregistration errors can produce significant differences in
radioligand quantification. In order to obtain accurate co-registration of PET and
MRI, we have developed a compatible bed system for mice and rats that allows to ac-
quire both imaging data in sequential mode without animal repositioning. A special
care was dedicated to preserve animal position and, with the introduction of external
markers, to facilitate the co-registration process.
6.3.1 Imaging systems and compatible bed development
MRI acquisitions were performed with a preclinical 7T scanner (Pharmascan, Bruker)
(see section 4.1), while PET scans with the YAP-(S)PET (see chapter 5). Since PET
and MRI are stand-alone scanners located in different rooms close to each other, it
was possible to develop a common bed that allows to move from one scanner to the
other by keeping the animal under anesthesia. The MRI scanner is equipped with
a plexiglas bed that includes a mask for gas anesthesia, while for the YAP-(S)PET
scanner, a carbon fiber bed is used which is incompatible with MRI. Therefore, we
manufactured a steel support for the YAP-(S)PET scanner, specifically designed to
embed the MRI plexiglas bed (see Figure 6.13).
Once MRI scans were performed, the bed was removed, transported to the PET
scan and mounted on the steel support. As much as the transportation process may
be accurate, slight misalignments can always occur due to translation offsets of the
bed during positioning. In order to limit this problem, external markers visible in
both modalities were also placed within the bed. For both mice and rats imaging,
the fiducial markers were realized with 1 mm diameter glass capillaries filled with a
drop solution of 18F-FDG (volume = 10 µl, activity = 1-3 µCi, 37-111 kBq) which
are visible with both modalities. Since for MRI, the radiofrequency coils for mice
have a reduced space compared to rat’ss coil, the fiducial markers were differently
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Figure 6.13: The YAP-(S)PET steel support for the MRI plexiglas bed. (B) and (C): a
mouse (on the left) and a rat (on the right) placed on the MRI plexiglas bed and ready to
be inserted in the MRI or YAP-(S)PET scanner, respectively. (D) Zoom of the half crown
where capillaries for rats acquisition are inserted.
placed. For rats, the capillaries were inserted inside a plexiglas half crown specifically
developed with four holes in which the capillaries were fitted. This half crown is
firmly fixed to the top of the bed above the head of the animal (see Figure 6.13). For
mice, three fiducial markers were placed on the bottom of the bed with slight shift
on the axis direction in order to cover a wider span on axis direction and to get a
more accurate co-registration.
6.3.2 Phantom tests: Image quality
To test the MRI-PET compatible bed support and co-registration accuracy, phantom
acquisition were performed using the NEMA Image Quality (IQ) phantom [180]. The
IQ is a plexiglas cylinder consisting of three parts: a central fillable chamber with
30 mm diameter and 30 mm long; a lid attached to the uniform region containing
two region chambers (15 mm in length and 8 mm of internal , 10 mm external 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and 1 mm wall thickness); a 20 mm solid final part with 5 fillable rods with of 1, 2,
3, 4 and 5 mm in diameter (see Figure 2). MRI scans were acquired with IQ filled
with radioactive solution (10 MBq or 260 µCi of 18F-FDG) and placed on the MRI
bed. Than, the bed was moved to the YAP-(S)PET system, mounted on the steel
support and PET images were acquired. MR images T1-weighted were acquired in
2D with a spin-echo sequence with an echo time (TE) of 10 ms, a repetition time
(TR) of 470 ms and a matrix of 256 × 256 pixels and 30 slices for a FOV of 6
× 4 cm. For PET, a static acquisition in 3D mode (without septa) was acquired
with 80 Mevents. The data acquired in list mode binary format were reformatted
with a Single Slice Rebinning Algorithm (SSRB) with a maximum span fixed to
eleven Lines of Response (LOR). Sinograms were reconstructed with a Maximum
Likelihood Expectation Maximization (ML-EM) with 30 iterations. No markers were
used for the IQ MRI and PET acquisitions, but the geometrical characteristics of the
phantom were utilized as reference points in the co-registration process.
6.3.3 In vivo imaging
In vivo imaging experiments were performed on both healthy mice (C57BL6) and
rats (Lewis) focused on the central nervous system (brain and spinal cord). To
normalize 18F-FDG uptake within the brain, animals were fasted for 12-14 hours
prior to imaging exams. Before animals preparation, the fiducial markers were filled
with a drop of a solution of 18F-FDG and inserted in the predisposed support (see
Figure 6.13). In order to not saturate the PET images, markers should have as low
activity as possible to be visible in PET acquisition and not to impair image quality.
The fiducial markers were filled with 3 µCi and 1 µCi of radiotracer for rats and mice,
respectively.
Prior to anesthesia with isofluorane gas mixed to oxygen, a catheter filled with
physiological serum was placed in the tail vein The animal was then placed within
the MRI bed, acquired with the MRI scanner and, once finished and at the end of the
image acquisitions the animal bed was transferred to the YAP-(S)PET room where
PET exam was done post i.v. administration of 18F-FDG (37 MBq in rats and 15
MBq in mice). MRI was performed with a FOV size equal to (4 × 4 × 6 cm), using
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a 3D T2 weighted spin-echo sequence with a rare factor of 8, matrix size of 128 ×
128 × 256 TR/TE= 3000/10ms in rats. In mice studies, the MRI acquisition was
performed with a FOV size equal to the YAP-(S)PET (4 × 4 × 6cm), using a 3D
T2 weighted spin-echo sequence with a rare factor of 8, matrix size of 128 × 128 ×
256 TR/TE= 1700/30ms in mice. PET images were acquired in 3D mode after an
uptake time of 45 minutes and 20 and 40 Mevents were acquired for rats and mice,
respectively. As for IQ acquisitions, the PET data were stored in list mode binary
format, reorganized by a SSR algorithm with a maximum span fixed to 11 LOR and
sinograms were reconstructed with ML-EM with 30 iterations.
6.3.4 Co-registration
The co-registration process was performed using the point-based registration tech-
nique. This method is based on the identification of corresponding three-dimensional
points in images produced by the two different modalities. A transformation ma-
trix is inferred by the points identification and then used to transform the whole
images [181]. To this purpose, the commercial software PMOD [182] was used. The
MRI and PET images were opened with the Fusion tool, marks corresponding to
geometrical references (for IQ phantom) or to the centroid of the fiducial markers
(animal studies) set in the two images and then let the software to calculate the
rigid-body transformation T(a,b, c,x, y, z) which brings the two spatial arrangements
of reference points into optimal agreement. Regions of Interest (ROIs) drawn on the
fused images were used for quantification purposes.
6.3.5 Results
Phantom tests: Image quality
For the Image Quality phantom co-registration, the centers of the larger filled rods
(diameters from 5 to 2 mm) were taken as reference points on both MRI and PET
images (see Figure 6.14). Due to partial volume effects and resolution limits, the
smallest hole (1 mm2 was not visible on PET image [183]). In order to quantify
the radioactivity, ROIs were drawn on MRI images on the 30 mm central section
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and on the five rods drawn. As expected, the activity concentration underestimation
increases with the reduction of the dimensions of the object under evaluation. As
shown in Figure 6.14, the underestimation for 1 mm rod approaches 90%. On the
other hand, the higher spatial resolution of the MRI allows to clearly distinguish even
the 1 mm hole that was not visible in the PET image. In fact, the MRI Intensity pro-
files through the diameter of the 5 IQ rods is nearly constant (see Figure 6.15). With
MRI, is then possible to determine the real extension of structures heavily underesti-
mated in PET images, thus allowing the application of the Recovery coefficient [122]
to correct for the partial volume effects.
Figure 6.14: Top: Sketch and photo of the Image Quality NEMA phantom. Bottom:
(Right): two series of transaxial slides of the MRI (top line), PET (middle) and co-registered
(bottom) images, before and after the co-registration.
Thanks to the external markers, clearly visible on both imaging modalities, MRI
and PET data from rats and mice were easily co-registered (see figure 6.16 and figure
6.17).
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Figure 6.15: Intensity profiles through the 1, 2, 3, 4, and 5 hot rods of the NEMA Image
Quality phantom from MRI data (in black) and PET data (in red).
Against the low resolved PET images, different brain structures were clearly dis-
tinguished on the co-registered 3D MRI images (see Figure 6.16) acquired with a
spatial resolution of 156 × 312 × 625 µm3.
6.3.6 Discussion
In the last 15 years, the development of combined PET/MRI systems have moved
towards fully integrated systems in which PET and MRI could be performed simul-
taneously [172,175–179]. To overcome technical incompatibilities, several approaches
have been pursued. The first one used optical fibers to lead scintillation light out-
side the fringe of the magnetic field or at least outside the MRI field of view (FOV).
Other approaches rely on special magnet designs, such as in split MRI tomographs,
where the PET detector is built in between two magnets, or field cycled MRI, where
the magnet is shut down during PET data acquisition [177]. Alternative designs of
small-animal PET-MRI and also a first clinical [184] have been based on compact,
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Figure 6.16: MRI (top raw), PET (middle raw) and fused images (bottom rod) of the brain
of an healthy rat.
solid-state silicon photo sensors - so-called avalanche photodiodes (APDs)- that are
not sensitive to magnetic fields [185]. On one hand these approaches are of great
interest since simultaneous PET/MRI acquisitions can be performed, while on the
other hand the hardware solutions are challenging and expensive. In particular, in
several preclinical imaging centers where both MRI and PET systems are already
available as independent systems, the development of a dedicated system that al-
low co-registration of both modalities is of primary importance. The proposed MRI
compatible bed system for direct co-registration of MRI and PET data can be easily
implemented and allows the reduction of misregistration due to animal positioning.
In both phantom and animal studies (see Figure 6.14 and 6.17), ROIs are easily
identified on MRI especially for small regions which are not visible on PET images.
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Figure 6.17: Fig 5: Left: MRI (top raw), PET (middle raw) and fused images (bottom
rod) of the brain of an healthy mouse. Right: MRI (top) and PET (middle raw) ROI on
brain structures and spinal cord.
A typical example, that reinforced the necessity of MRI for PET analysis is the
smallest hole of the IQ. With the excellent soft-tissue discrimination of the MRI, the
central nervous system is clearly defined respect to other anatomical techniques like
CT. This makes MRI a suitable and complementary modality to PET. Nevertheless,
the PET/MRI co-registration is made harder respect to PET/CT by the necessity
to derive the attenuation correction coefficient from PET/MRI measurements [186].
In fact, while in PET/CT PET attenuation data can be derived from transforming
available CT transmission images into maps of attenuation coefficients at 511 keV,
no such transmission data are available for PET/MRI [178].
Conclusion
We have developed an MRI compatible bed system for direct PET/MRI co-registration
on both rats and mice. The co-registration process in based on external fiducial mark-
ers. The system was tested on both phantom and animal studies. In these studies
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we especially focused on the validation of the system. In general, a good alignment
of anatomical structures and the fiducial markers was evident upon inspection of the
fused images of both phantom and animals. The simplicity of the developed sys-
tem and the good quality of the obtained fused images push to extend the use of
the system also on diseased animals. In particular, it could be particularly useful
in neurological disease studies. Besides, since the YAP-(S)PET scanner can operate
in both PET and SPECT modalities, the MRI compatible bed with the external
markers could also be used in SPECT/MRI studies.
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Chapter 7
Conclusion
This thesis deals with the experience in a Center of Excellence in Preclinical Imaging
(CEIP): from the set-up of the PET/SPECT laboratory to the routine experimental
activity. The CEIP is a laboratory realized within an Academic/Industry partnership
and offers to universities, research centers and companies know-how and methodolo-
gies based on imaging techniques in order to facilitate and speed up the process of
development of new diagnostic and therapeutic solutions. The CEIP is located inside
the Bioindustry Park Silvano Fumero S.p.A., a science and technology park located
in Canavese, an area near Turin and is equipped with several state of the art imag-
ing device: MRI systems, PET/SPECT and CT scanners, Ultra sound and Optical
systems (see chapter 4.
In particular, the MRI systems are: a clinical 0.2 T system for imaging large animals
and rodents with dedicated coils and a preclinical 3 and 7 T system with a horizontal
magnet.
PET/SPECT investigations are carried on with the YAP-(S)PET scanner, origi-
nally developed at the Department of Physics of the Universities of Ferrara and
Pisa, Italy [101,102] and from 2003, produced and commercialized by the small ital-
ian company I.S.E. Ingegneria dei Sistemi Elettronici s.r.l., Pisa, Italy [103]. The
PET/SPECT/CT scanner is the Triumph Trimodality system [97], a fully integrated
SPECT/PET/CT hardware and software platform optimized for small animals in
pre-clinical and biomedical research applications.
The Ultra sound system is a VisualSonics-VeVo 2100, while the optical system is the
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Pear Imager working in the near-infrared spectral region. Both systems are specifi-
cally developed for small animal imaging.
This thesis mainly describes two topics of the experience within the CEIP: the
set-up of the PET/SPECT laboratory and a few small animal imaging studies. Con-
cerning the set-up of the PET/SPECT laboratory, we focused on the radioprotection
issues, in particular:
• features of the employed sources.
• Selection of the rooms reserved for radioactive employing and description of the
equipment positioning.
• Shielding calculation.
• Evaluation of the radiation exposure to both personnel and public.
• Management of the radioactive wastes and residuals.
• Classification of the areas and of the workers.
The employed unsealed sources are both PET and SPECT radiotracers provided
by Advanced Accelerator Applications. For PET activities both 18F and 68Ga can be
employed, while for SPECT studies 99mTc, 177Lu and 111Lu are available.
PET/SPECT imaging consists in injecting radioactive compounds in the subject
under investigation. As a consequence, once injected, the animals become radioactive
and are the main source of radiation for both environment and workers. Furthermore,
during imaging, typically shielding is not an option, so the imaging systems ideally
should be located away from where people are likely to sit or stand. Following the
ALARA principle, we planned to reserve three rooms for all the activities connected
with the PET/SPECT imaging: the scan, the console and the storage room. The
shielding calculations and the dose evaluation to both exposed personnel and public
have been performed.
The shielding calculation highlighted that for the scan room, the total effective
rate dose at 1 meter obtained by summing all the effective doses of each isotopes is
11 mSv/year. Hence, the area has to be classified as controlled. About the shielding,
in order to obtain a dose of 1 mSv/year for all the scan room’s adjacent areas, a 1.5
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mm lead thickness was applied on all the walls of the scan room. For the storage
room, 2 mm of lead were necessary on all the walls.
The evaluation of the dose to exposed personnel has been carried out on the basis
of the PET/SPECT laboratory workload, in particular, by taking in account the total
activity per each handling, the number of animals scanned per day and the injected
activity per animal. The total effective dose (Ebody) and of the equivalent dose to
the eye Heye obtained (around 5 and 8 mSv/y, respectively) could lead to classify the
workers in category B, but the high equivalent dose to the hands (Hhands), close to
the limit for the A exposed workers, led us to classify the PET/SPECT laboratory
workers in category A. The exposed personnel will then be subjected to dosimetric
control by both body and extremities dosimeters and to medical supervision that
foresees medical checks performed every six months by an Authorized Doctor. All
the remaining CEIP people will be considered as Public.
About the management of the solid waste, it was evaluated that all the wastes will
be kept in the shielded container inside the scan or the storage room for a time span
of at least 5 half lives of the relative employed source and anyway till the radioactive
concentration will be lower than 1 Bq/g, as stated by the D.Lgs. 230/95 and s.m.i.
Concerning the radioactive animals, two situations were taken into account. When
the animals are injected with the short half life radioisotopes (18F and 68Ga) and are
not sacrificed, the day after the PET scan they can be returned to the vivarium. On
the other hand, the animals injected with radioisotopes with longer half lives (177Lu
and 111In) and not sacrificed, will be stored in the ventilated cabinet placed inside
the storage room for a time span of at least 5 half lives of the employed source and
anyway till the radioactive concentration will be lower than 1 Bq/g, as stated by the
D.Lgs. 230/95 and s.m.i.
About animal experiments, a few case studies have been reported. Since the in-
stallation of the trimodality PET/SPECT/CT Triumph scanner has been completed
in the 2011 fall, only studies performed with the YAP-(S)PET scanner are reported.
In particular:
• a PET study performed with 18F and 68Ga to assess the response to Dasatinib
treatment in PC-3 prostate tumor-bearing nude mice.
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• A longitudinal SPECT concerning the evaluation of the 99mTc-rhAnnexin V-128
imaging effectiveness for diagnosis and monitoring anti-rheumatic therapies in
a collagen induced arthritis (CIA) model in mice.
• A multimodality study realized by combining the 7 T MRI scanner with the
YAP-(S)PET scanner. The PET/MRI acquisitions were performed in sequen-
tial mode with a hand-made bed support that allowed to keep the animal in a
fixed position.
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